# EDGAR Filing Document

**Accession Number:** 0001111928
**File Stem:** 0001111928-25-000168
**Filing Date:** 2025-11
**Character Count:** 152784
**Document Hash:** 4f474e56ae57c5a481e49991687b4048
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001111928-25-000168.hdr.sgml**: 20251104

**ACCESSION NUMBER**: 0001111928-25-000168

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 83

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251104

**DATE AS OF CHANGE**: 20251104

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IPG PHOTONICS CORP
- **CENTRAL INDEX KEY:** 0001111928
- **STANDARD INDUSTRIAL CLASSIFICATION:** SEMICONDUCTORS & RELATED DEVICES [3674]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 043444218
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33155
- **FILM NUMBER:** 251450093

**BUSINESS ADDRESS:**
- **STREET 1:** 377 SIMARANO DRIVE
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01752
- **BUSINESS PHONE:** 5083731100

**MAIL ADDRESS:**
- **STREET 1:** 377 SIMARANO DRIVE
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01752

?xml version='1.0' encoding='ASCII'? ipgp-20250930

<u>[**Table of Contents**](#i16ef846430f9402292f85303557ea7bd_7)</u>

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

(Mark One)

**☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2025

OR

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from to .

Commission File Number 001-33155

![image.jpg](ipgp-20250930_g1.jpg)

**IPG PHOTONICS CORPORATION**

*(Exact name of registrant as specified in its charter)*

---

| | |
|:---|:---|
| **Delaware** | **04-3444218** |
| *(State or other jurisdiction of* | *(I.R.S. Employer* |
| *incorporation or organization)* | *Identification Number)* |
| **377 Simarano Drive, Marlborough, Massachusetts** | **01752** |
| *(Address of principal executive offices)* | *(Zip code)* |

---

Registrant's telephone number, including area code: **(508) 373-1100**

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| <u>Title of each class</u> | <u>Trading Symbol</u> | <u>Name of each exchange on which registered</u> |
| **Common Stock, par value $0.0001 per share** | **IPGP** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes ☑&nbsp;&nbsp;&nbsp;&nbsp;No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data file required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☑&nbsp;&nbsp;&nbsp;&nbsp;No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large Accelerated Filer | ☑ | Accelerated Filer | ☐ |
| Non-Accelerated Filer | ☐ | Smaller Reporting Company | ☐ |
| Emerging Growth Company | ☐ | | |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐&nbsp;&nbsp;&nbsp;&nbsp;No ☑

As of November 3, 2025, there were 42,124,481 shares of the registrant's common stock outstanding.

------

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| <u>[Part I. Financial Information](#i16ef846430f9402292f85303557ea7bd_10)</u> | <u>[1](#i16ef846430f9402292f85303557ea7bd_10)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 1. Unaudited Interim Financial Statements](#i16ef846430f9402292f85303557ea7bd_13)</u> | <u>[1](#i16ef846430f9402292f85303557ea7bd_13)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Balance Sheets:](#i16ef846430f9402292f85303557ea7bd_16)[September](#i16ef846430f9402292f85303557ea7bd_16)[30, 2025 and December 31, 2024](#i16ef846430f9402292f85303557ea7bd_16)</u> | <u>[1](#i16ef846430f9402292f85303557ea7bd_16)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Operations: Three and](#i16ef846430f9402292f85303557ea7bd_19)[Nine](#i16ef846430f9402292f85303557ea7bd_19)[Months Ended](#i16ef846430f9402292f85303557ea7bd_19)[September](#i16ef846430f9402292f85303557ea7bd_19)[30, 2025 and 2024](#i16ef846430f9402292f85303557ea7bd_19)</u> | <u>[2](#i16ef846430f9402292f85303557ea7bd_19)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Comprehensive Income: Three and](#i16ef846430f9402292f85303557ea7bd_22)[Nine](#i16ef846430f9402292f85303557ea7bd_22)[Months Ended](#i16ef846430f9402292f85303557ea7bd_22)[September](#i16ef846430f9402292f85303557ea7bd_22)[30, 2025 and 2024](#i16ef846430f9402292f85303557ea7bd_22)</u> | <u>[3](#i16ef846430f9402292f85303557ea7bd_22)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Cash Flows:](#i16ef846430f9402292f85303557ea7bd_25)[Nine](#i16ef846430f9402292f85303557ea7bd_25)[Months Ended](#i16ef846430f9402292f85303557ea7bd_25)[September](#i16ef846430f9402292f85303557ea7bd_25)[30, 2025 and 2024](#i16ef846430f9402292f85303557ea7bd_25)</u> | <u>[4](#i16ef846430f9402292f85303557ea7bd_25)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Equity: Three and](#i16ef846430f9402292f85303557ea7bd_28)[Nine](#i16ef846430f9402292f85303557ea7bd_28)[Months Ended](#i16ef846430f9402292f85303557ea7bd_28)[Se](#i16ef846430f9402292f85303557ea7bd_28)[ptember](#i16ef846430f9402292f85303557ea7bd_28)[30](#i16ef846430f9402292f85303557ea7bd_28)[, 2025 and 2024](#i16ef846430f9402292f85303557ea7bd_28)</u> | <u>[5](#i16ef846430f9402292f85303557ea7bd_28)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Notes to Condensed Consolidated Financial Statements](#i16ef846430f9402292f85303557ea7bd_31)</u> | <u>[6](#i16ef846430f9402292f85303557ea7bd_31)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#i16ef846430f9402292f85303557ea7bd_85)</u> | <u>[17](#i16ef846430f9402292f85303557ea7bd_85)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 3. Quantitative and Qualitative Disclosures About Market Risk](#i16ef846430f9402292f85303557ea7bd_109)</u> | <u>[27](#i16ef846430f9402292f85303557ea7bd_109)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 4. Controls and Procedures](#i16ef846430f9402292f85303557ea7bd_112)</u> | <u>[28](#i16ef846430f9402292f85303557ea7bd_112)</u> |
| <u>[Part II. Other Information](#i16ef846430f9402292f85303557ea7bd_115)</u> | <u>[29](#i16ef846430f9402292f85303557ea7bd_115)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 1. Legal Proceedings](#i16ef846430f9402292f85303557ea7bd_118)</u> | <u>[29](#i16ef846430f9402292f85303557ea7bd_118)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 1A. Risk Factors](#i16ef846430f9402292f85303557ea7bd_121)</u> | <u>[29](#i16ef846430f9402292f85303557ea7bd_121)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#i16ef846430f9402292f85303557ea7bd_124)</u> | <u>[29](#i16ef846430f9402292f85303557ea7bd_124)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 3. Defaults Upon Senior Securities](#i16ef846430f9402292f85303557ea7bd_127)</u> | <u>[29](#i16ef846430f9402292f85303557ea7bd_127)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 4. Mine Safety Disclosures](#i16ef846430f9402292f85303557ea7bd_130)</u> | <u>[29](#i16ef846430f9402292f85303557ea7bd_130)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 5. Other Information](#i16ef846430f9402292f85303557ea7bd_133)</u> | <u>[30](#i16ef846430f9402292f85303557ea7bd_133)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 6. Exhibits](#i16ef846430f9402292f85303557ea7bd_139)</u> | <u>[30](#i16ef846430f9402292f85303557ea7bd_139)</u> |
| <u>[Signatures](#i16ef846430f9402292f85303557ea7bd_142)</u> | <u>[31](#i16ef846430f9402292f85303557ea7bd_142)</u> |

---

------

<u>[**Table of Contents**](#i16ef846430f9402292f85303557ea7bd_7)</u>

**PART I—FINANCIAL INFORMATION**

**ITEM 1. UNAUDITED INTERIM FINANCIAL STATEMENTS**

**IPG PHOTONICS CORPORATION**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
| | **September 30,**<br>**2025** | **December 31,**<br>**2024** |
| | **(In thousands, except share and per share data)** | **(In thousands, except share and per share data)** |
| **ASSETS** | **ASSETS** | **ASSETS** |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $346026 | $620040 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Short-term investments | 524359 | 310152 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 166384 | 171131 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | 323934 | 284780 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid income taxes | 27847 | 17592 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 45963 | 27300 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 1434513 | 1430995 |
| Long-term investments | 30166 |  |
| Deferred income taxes, net | 119552 | 115031 |
| Goodwill | 71650 | 67241 |
| Intangible assets, net | 52226 | 55376 |
| Property, plant and equipment, net | 622122 | 588375 |
| Other assets | 50734 | 32246 |
| Total assets | $2380963 | $2289264 |
| **LIABILITIES AND EQUITY** | **LIABILITIES AND EQUITY** | **LIABILITIES AND EQUITY** |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $40225 | $35385 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 171028 | 152048 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | 2128 | 17586 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 213381 | 205019 |
| Other long-term liabilities and deferred income taxes | 62770 | 59774 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 276151 | 264793 |
| Commitments and contingencies (Note 11) |  |  |
| IPG Photonics Corporation equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.0001 par value, 175,000,000 shares authorized; 56,909,427 and 42,119,624 shares issued and outstanding, respectively, at September 30, 2025; 56,632,974 and 42,548,561 shares issued and outstanding, respectively, at December 31, 2024. | 6 | 6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treasury stock, at cost, 14,789,803 and 14,084,413 shares held at September 30, 2025 and December 31, 2024, respectively.  | (1551924) | (1505321) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 1063762 | 1035285 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 2631694 | 2613868 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (38726) | (119367) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 2104812 | 2024471 |
| Total liabilities and stockholders' equity | $2380963 | $2289264 |

---

See notes to Condensed Consolidated Financial Statements.

------

<u>[**Table of Contents**](#i16ef846430f9402292f85303557ea7bd_7)</u>

**IPG PHOTONICS CORPORATION**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| | **(In thousands, except per share data)** | **(In thousands, except per share data)** | **(In thousands, except per share data)** | **(In thousands, except per share data)** |
| Net sales | $250792 | $233143 | $729306 | $742797 |
| Cost of sales | 151787 | 179054 | 446916 | 494986 |
| Gross profit | 99005 | 54089 | 282390 | 247811 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | 23771 | 22233 | 73753 | 67718 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development | 30358 | 27177 | 88631 | 84045 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 35092 | 32660 | 102782 | 95420 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss from divestiture and sale of assets |  | 197651 |  | 190201 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment of long-lived assets |  | 26566 |  | 26566 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring charges | 425 |  | 425 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on foreign exchange | 1504 | 1148 | 7013 | 6067 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 91150 | 307435 | 272604 | 470017 |
| Operating income (loss) | 7855 | (253346) | 9786 | (222206) |
| Other income, net: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income, net | 7283 | 11103 | 22728 | 38058 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income (loss), net | 516 | (271) | 2026 | 248 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other income | 7799 | 10832 | 24754 | 38306 |
| Income (loss) before provision for income taxes  | 15654 | (242514) | 34540 | (183900) |
| Provision for income taxes | 8191 | (8920) | 16714 | 5441 |
| Net income (loss) | $7463 | $(233594) | $17826 | $(189341) |
| Net income (loss) per common share: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.18 | $(5.33) | $0.42 | $(4.22) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.18 | $(5.33) | $0.42 | $(4.22) |
| Weighted average common shares outstanding: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | 42199 | 43837 | 42427 | 44901 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | 42556 | 43837 | 42659 | 44901 |

---

See notes to Condensed Consolidated Financial Statements.

------

<u>[**Table of Contents**](#i16ef846430f9402292f85303557ea7bd_7)</u>

**IPG PHOTONICS CORPORATION**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Net income (loss) | $7463 | $(233594) | $17826 | $(189341) |
| Other comprehensive (loss) income, net of tax: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustments and other | (1486) | 158121 | 80641 | 143799 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other comprehensive (loss) income | (1486) | 158121 | 80641 | 143799 |
| Comprehensive income (loss) | $5977 | $(75473) | $98467 | $(45542) |

---

See notes to Condensed Consolidated Financial Statements.

------

<u>[**Table of Contents**](#i16ef846430f9402292f85303557ea7bd_7)</u>

**IPG PHOTONICS CORPORATION**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** |
| | **(In thousands)** | **(In thousands)** |
| **Cash flows from operating activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) | $17826 | $(189341) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 46799 | 46623 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | (7238) | (18763) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 32793 | 29378 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment of long-lived assets |  | 26566 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized loss (gain) on foreign currency transactions | 3378 | (118) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss from divestiture and sale of assets |  | 190201 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provisions for inventory, warranty and bad debt | 31766 | 76434 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of premium/discount on investments | (11703) | (15676) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 3889 | 2841 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in assets and liabilities that provided (used) cash, net of acquisitions: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | 11373 | 51884 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (52005) | 29760 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | (11589) | (4501) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 7414 | 4272 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other liabilities | (1024) | (36743) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income and other taxes payable | (25144) | (18705) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 46535 | 174112 |
| **Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of and deposits on property, plant and equipment | (60907) | (75358) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sales of property, plant and equipment | 605 | 28538 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of investments | (866402) | (423176) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from maturities of investments | 633731 | 966214 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash outflow from divestiture |  | (25324) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 69 | 385 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash (used in) provided by investing activities | (292904) | 471279 |
| **Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments for taxes related to net share settlement of equity awards less proceeds from issuance of common stock under employee stock option and purchase plans | (4316) | 1870 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase of treasury stock net of excise tax, at cost | (46603) | (286479) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities | (50919) | (284609) |
| Effect of changes in exchange rates on cash and cash equivalents | 23274 | 8415 |
| Net (decrease) increase in cash and cash equivalents | (274014) | 369197 |
| Cash and cash equivalents — Beginning of period | 620040 | 514674 |
| Cash and cash equivalents — End of period | $346026 | $883871 |
| **Supplemental disclosure of cash flow information:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid for interest | $136 | $95 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid for income taxes | $44258 | $38905 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-cash transactions: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Demonstration units transferred from inventory to other assets | $5587 | $4384 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory transferred to machinery and equipment | $1595 | $1816 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additions to property, plant and equipment included in accounts payable | $1622 | $3037 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Leased assets obtained in exchange for new operating lease liabilities | $6237 | $3077 |

---

See notes to Condensed Consolidated Financial Statements.

------

<u>[**Table of Contents**](#i16ef846430f9402292f85303557ea7bd_7)</u>

**IPG PHOTONICS CORPORATION**

**CONDENSED CONSOLIDATED STATEMENTS OF EQUITY**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** |
| | **Common Stock** | **Common Stock** | **Treasury Stock** | **Treasury Stock** | **Additional Paid-In Capital** | **Retained Earnings** | **Accumulated Other Comprehensive (Loss) Income** | **Total Stockholders' Equity** |
| **(In thousands, except share data)** | **Shares** | **Amount** | **Shares** | **Amount** | **Additional Paid-In Capital** | **Retained Earnings** | **Accumulated Other Comprehensive (Loss) Income** | **Total Stockholders' Equity** |
| **Balance, July 1, 2025** | **42329918** | $**6** | **(14575395)** | $**(1535525)** | $**1053080** | $**2624231** | $**(37240)** | $**2104552** |
| &nbsp;&nbsp;Vesting of RSUs and PSUs, net of shares withheld for taxes, and exercise of stock options | 4114 |  |  |  | (63) |  |  | (63) |
| &nbsp;&nbsp;Purchased common stock | (214408) |  | (214408) | (16399) |  |  |  | (16399) |
| &nbsp;&nbsp;Stock-based compensation |  |  |  |  | 10745 |  |  | 10745 |
| &nbsp;&nbsp;Net income |  |  |  |  |  | 7463 |  | 7463 |
| &nbsp;&nbsp;Foreign currency translation adjustments and other |  |  |  |  |  |  | (1486) | (1486) |
| **Balance, September 30, 2025** | **42119624** | $**6** | **(14789803)** | $**(1551924)** | $**1063762** | $**2631694** | $**(38726)** | $**2104812** |
| **Balance, July 1, 2024** | **44225282** | $**6** | **(12358941)** | $**(1373525)** | $**1014094** | $**2839647** | $**(226852)** | $**2253370** |
| &nbsp;&nbsp;Vesting of RSUs and PSUs, net of shares withheld for taxes, and exercise of stock options | 6858 |  |  |  | 78 |  |  | 78 |
| &nbsp;&nbsp;Purchased common stock | (984060) |  | (984060) | (74459) |  |  |  | (74459) |
| &nbsp;&nbsp;Stock-based compensation |  |  |  |  | 11096 |  |  | 11096 |
| &nbsp;&nbsp;Net loss |  |  |  |  |  | (233594) |  | (233594) |
| &nbsp;&nbsp;Foreign currency translation adjustments and other |  |  |  |  |  |  | 158121 | 158121 |
| **Balance, September 30, 2024** | **43248080** | $**6** | **(13343001)** | $**(1447984)** | $**1025268** | $**2606053** | $**(68731)** | $**2114612** |
|  | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **Common Stock** | **Common Stock** | **Treasury Stock** | **Treasury Stock** | **Additional Paid In Capital** | **Retained Earnings** | **Accumulated Other Comprehensive (Loss) Income** | **Total Stockholders' Equity** |
| **(In thousands, except share data)** | **Shares** | **Amount** | **Shares** | **Amount** | **Additional Paid In Capital** | **Retained Earnings** | **Accumulated Other Comprehensive (Loss) Income** | **Total Stockholders' Equity** |
| **Balance, January 1, 2025** | **42548561** | $**6** | **(14084413)** | $**(1505321)** | $**1035285** | $**2613868** | $**(119367)** | $**2024471** |
| &nbsp;&nbsp;Vesting of RSUs and PSUs, net of shares withheld for taxes, and exercise of stock options | 234174 |  |  |  | (6783) |  |  | (6783) |
| &nbsp;&nbsp;Common stock issued under employee stock purchase plan | 42279 |  |  |  | 2467 |  |  | 2467 |
| &nbsp;&nbsp;Purchased common stock | (705390) |  | (705390) | (46603) |  |  |  | (46603) |
| &nbsp;&nbsp;Stock-based compensation |  |  |  |  | 32793 |  |  | 32793 |
| &nbsp;&nbsp;Net income |  |  |  |  |  | 17826 |  | 17826 |
| &nbsp;&nbsp;Foreign currency translation adjustments and other |  |  |  |  |  |  | 80641 | 80641 |
| **Balance, September 30, 2025** | **42119624** | $**6** | **(14789803)** | $**(1551924)** | $**1063762** | $**2631694** | $**(38726)** | $**2104812** |
| **Balance, January 1, 2024** | **46320671** | $**6** | **(9996767)** | $**(1161505)** | $**994020** | $**2795394** | $**(212530)** | $**2415385** |
| &nbsp;&nbsp;Vesting of RSUs and PSUs, net of shares withheld for taxes, and exercise of stock options | 238801 |  |  |  | (629) |  |  | (629) |
| &nbsp;&nbsp;Common stock issued under employee stock purchase plan | 34842 |  |  |  | 2499 |  |  | 2499 |
| &nbsp;&nbsp;Purchased common stock | (3346234) |  | (3346234) | (286479) |  |  |  | (286479) |
| &nbsp;&nbsp;Stock-based compensation |  |  |  |  | 29378 |  |  | 29378 |
| &nbsp;&nbsp;Net loss |  |  |  |  |  | (189341) |  | (189341) |
| &nbsp;&nbsp;Foreign currency translation adjustments and other |  |  |  |  |  |  | 143799 | 143799 |
| **Balance, September 30, 2024** | **43248080** | $**6** | **(13343001)** | $**(1447984)** | $**1025268** | $**2606053** | $**(68731)** | $**2114612** |

---

See notes to Condensed Consolidated Financial Statements.

------

<u>[**Table of Contents**](#i16ef846430f9402292f85303557ea7bd_7)</u>

 **IPG PHOTONICS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(In thousands, except share and per share data)**

**1. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES**

*Basis of Presentation* — The accompanying unaudited Condensed Consolidated Financial Statements have been prepared by IPG Photonics Corporation, or "IPG", "its" or the "Company". Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). The Condensed Consolidated Financial Statements include the Company's accounts and those of its subsidiaries. All intercompany balances have been eliminated in consolidation. These Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and notes thereto in the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

In the opinion of the Company's management, the financial information for the interim periods presented reflects all adjustments necessary for a fair presentation of the Company's financial position, results of operations and cash flows. The results reported in these Condensed Consolidated Financial Statements are not necessarily indicative of results that may be expected for the entire year.

*Change in Accounting Estimate* — During the fourth quarter of 2024, the Company completed an assessment of the useful lives of certain machinery and equipment, resulting in a change in the upper end of the range for these assets from 7 years to 10 years based upon the Company's experience of historical usage. The change in estimate resulted in a decrease of depreciation expense reflected in the Company's Condensed Consolidated Statements of Operations. As a result of this change, Operating income increased approximately $1,000 and $2,800 for the three and nine months ended September 30, 2025, respectively, Net income increased approximately $700 and $2,100 for the three and nine months ended September 30, 2025, respectively, and diluted net income per common share increased approximately $0.02 and $0.05 for the three and nine months ended September 30, 2025, respectively.

Subsequent Events — The Company has considered the impact of subsequent events through the filing date of these financial statements. There were no events through the filing date of these financial statements required to be disclosed.

**2. RECENT ACCOUNTING PRONOUNCEMENTS**

*Adopted Pronouncement* — In November 2023, the FASB issued ASU No. 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures" ("ASU 2023-07"), which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses on an annual and interim basis. Under the new guidance an entity is required to disclose the title and position of the chief operating decision maker ("CODM") and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. The ASU also requires that an entity that has a single reportable segment provide all the disclosures required by this ASU and all existing segment disclosures in Topic 280. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company has adopted ASU 2023-07. Refer to Note 15, "Segment Reporting."

*Pronouncements Currently Under Evaluation* — In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures" ("ASU 2023-09"), which requires an entity on an annual basis to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The guidance also requires an entity to disclose on an annual basis information about income taxes paid. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The Company is evaluating the impact of this ASU on its disclosures.

In November 2024, the FASB issued ASU No. 2024-03, "Income Statement - Reporting Comprehensive Income - Expense Aggregation Disclosures (Subtopic 220-40)" ("ASU 2024-03"), which requires more detailed disaggregated disclosure of income statement expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027. The Company is evaluating the impact of this ASU on its disclosures.

In July 2025, the FASB issued ASU No. 2025-05, "Financial Instruments - Credit Losses (Topic 326): Measurements of Credit Losses for Accounts Receivable and Contract Assets" ("ASU 2025-05"), which provides a practical expedient to apply ASC 326 to current accounts receivable and current contract assets. The practical expedient allows the Company to make a policy election to assume that current conditions as of the balance sheet date will not change for the remaining lives of the

------

<u>[**Table of Contents**](#i16ef846430f9402292f85303557ea7bd_7)</u>

**IPG PHOTONICS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)**

**(In thousands, except share and per share data)**

assets. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025, and interim reporting periods within those years. The Company is evaluating the impact of this ASU and does not expect that this standard will have a material impact on the Company's financial statements.

In September 2025, the FASB issued ASU No. 2025-06, "Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40)" ("ASU 2025-06"), which updates guidance regarding the requirements to begin capitalizing internal-use software. ASU 2025-06 is effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. The Company is evaluating the impact of this ASU on its financial statements.

**3. REVENUE FROM CONTRACTS WITH CUSTOMERS**

Sales are derived from products for different applications: fiber lasers, diode lasers, systems and accessories for materials processing; fiber lasers, diodes and amplifiers for advanced applications; and fiber lasers, systems and fibers for medical applications.

The following tables represent a disaggregation of revenue from contracts with customers:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **<u>Sales by Application</u>** |  |  |  |  |
| Materials processing | $219427 | $207063 | $627397 | $659201 |
| Other applications | 31365 | 26080 | 101909 | 83596 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $250792 | $233143 | $729306 | $742797 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **<u>Sales by Product</u>** |  |  |  |  |
| High Power Continuous Wave ("CW") Lasers | $76553 | $81325 | $222121 | $254343 |
| Medium Power CW Lasers | 21135 | 15110 | 66274 | 47082 |
| Pulsed Lasers | 34159 | 33470 | 108793 | 110825 |
| Quasi-Continuous Wave ("QCW") Lasers | 14771 | 10180 | 37300 | 36520 |
| Laser and Non-Laser Systems | 35590 | 35265 | 108398 | 111436 |
| Other Revenue including Other Lasers, Amplifiers, Service, Parts, and Accessories | 68584 | 57793 | 186420 | 182591 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $250792 | $233143 | $729306 | $742797 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **<u>Sales by Geography</u>** | | | | |
| North America | $62046 | $57294 | $192313 | $198163 |
| Europe: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Germany | 24499 | 25787 | 71501 | 66615 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 38194 | 41485 | 104599 | 154704 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Europe | 62693 | 67272 | 176100 | 221319 |
| Asia: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;China | 74135 | 61769 | 216167 | 189374 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Japan | 18187 | 14495 | 45653 | 41408 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 29797 | 29470 | 89765 | 82091 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Asia | 122119 | 105734 | 351585 | 312873 |
| Rest of World | 3934 | 2843 | 9308 | 10442 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $250792 | $233143 | $729306 | $742797 |

---

------

<u>[**Table of Contents**](#i16ef846430f9402292f85303557ea7bd_7)</u>

**IPG PHOTONICS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)**

**(In thousands, except share and per share data)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **<u>Timing of Revenue Recognition</u>** |  |  |  |  |
| Goods and services transferred at a point in time | $245481 | $223269 | $713379 | $713913 |
| Goods and services transferred over time | 5311 | 9874 | 15927 | 28884 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $250792 | $233143 | $729306 | $742797 |

---

One of the Company's customers accounted for 13% and 12% of the Company's net accounts receivable as of September 30, 2025 and December 31, 2024, respectively.

The Company recognizes revenue over time on contracts for the sale of large scale materials processing systems. The timing of customer payments on these contracts generally differs from the timing of revenue recognized. If revenue recognized exceeds customer payments, a contract asset is recorded and if customer payments exceed revenue recognized, a contract liability is recorded. Contract assets are included within prepaid expense and other current assets on the Condensed Consolidated Balance Sheets. Contract liabilities are included within accrued expenses and other current liabilities on the Condensed Consolidated Balance Sheets. Certain deferred revenues related to extended warranties in excess of one year from the balance sheet date are included within other long-term liabilities and deferred income taxes on the Condensed Consolidated Balance Sheets.

The following table reflects the changes in the Company's contract assets and liabilities for the nine months ended September 30, 2025 and 2024:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **September 30,**<br>**2025** | **January 1,**<br>**2025** |<br>**Change** | **September 30,**<br>**2024** | **January 1,**<br>**2024** |<br>**Change** |
| **Contract assets** |  |  |  |  |  |  |
| Contract assets | $2748 | $4737 | $(1989) | $10835 | $9383 | $1452 |
| **Contract liabilities** |  |  |  |  |  |  |
| Contract liabilities - current | 54893 | 56454 | (1561) | 52271 | 69219 | (16948) |
| Contract liabilities - long-term | 3116 | 2882 | 234 | 3015 | 2851 | 164 |

---

During the three months ended September 30, 2025 and 2024, the Company recognized revenue of $3,321 and $6,366, respectively, that was included in contract liabilities at the beginning of each year. During the nine months ended September 30, 2025 and 2024, the Company recognized revenue of $37,360 and $49,582 respectively, that was included in contract liabilities at the beginning of each year.

The following table represents the Company's remaining performance obligations from contracts that are recognized over time as of September 30, 2025:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Remaining Performance Obligations** | **Remaining Performance Obligations** | **Remaining Performance Obligations** | **Remaining Performance Obligations** | **Remaining Performance Obligations** | **Remaining Performance Obligations** | **Remaining Performance Obligations** |
| | **2025** <sup>(a)</sup> | **2026** | **2027** | **2028** | **2029** | **Thereafter** | **Total** |
| Revenue expected to be recognized for extended warranty agreements | $496 | $953 | $490 | $359 | $267 | $79 | $2644 |
| Revenue to be earned over time from contracts to sell large scale materials processing systems | 3825 | 6295 | 330 |  |  |  | 10450 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $4321 | $7248 | $820 | $359 | $267 | $79 | $13094 |

---

<sup>(a)</sup> For the three-month period beginning October 1, 2025.

**4. FAIR VALUE MEASUREMENTS**

The Company's financial instruments consist of cash equivalents, short-term and long-term investments, accounts receivable, accounts payable, and revolving lines of credit.

The valuation techniques used to measure fair value are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect internal market assumptions.

------

<u>[**Table of Contents**](#i16ef846430f9402292f85303557ea7bd_7)</u>

**IPG PHOTONICS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)**

**(In thousands, except share and per share data)**

These two types of inputs create the following fair value hierarchy: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company classifies its financial instruments according to the prescribed criteria.

The fair value of money market fund deposits, cash equivalent term deposits, accounts receivable, accounts payable and drawings on revolving lines of credit is reasonably close to their carrying amounts due to the short maturity of most of these instruments or as a result of the competitive market interest rates, which have been negotiated. The fair value of the Company's commercial paper, corporate bonds, U.S. Treasury and agency obligations and term deposits are based on Level 2 inputs.

The following table presents fair value information related to the Company's assets and liabilities measured at amortized cost on the Condensed Consolidated Balance Sheets:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fair Value Measurements at September 30, 2025** | **Fair Value Measurements at September 30, 2025** | **Fair Value Measurements at September 30, 2025** | **Fair Value Measurements at September 30, 2025** |
| | **Total** | **Level 1** | **Level 2** | **Level 3** |
| **Assets** | | | | |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Cash equivalents:** | | | | |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Money market fund deposits | $106108 | $106108 | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term deposits | 49874 |  | 49874 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercial paper | 14958 |  | 14958 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cash equivalents | 170940 | 106108 | 64832 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Short-term investments:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate bonds | 268195 |  | 268195 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercial paper | 181471 |  | 181471 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. Treasury and agency obligations | 71882 |  | 71882 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term deposits | 3104 |  | 3104 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total short-term investments | 524652 |  | 524652 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Long-term investments:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate bonds | 30170 |  | 30170 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total long-term investments | 30170 |  | 30170 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total** | $725762 | $106108 | $619654 | $— |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fair Value Measurements at December 31, 2024** | **Fair Value Measurements at December 31, 2024** | **Fair Value Measurements at December 31, 2024** | **Fair Value Measurements at December 31, 2024** |
| | **Total** | **Level 1** | **Level 2** | **Level 3** |
| **Assets** | | | | |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Cash equivalents:** | | | | |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Money market fund deposits | $77855 | $77855 | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercial paper | 163589 |  | 163589 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. Treasury and agency obligations | 47770 |  | 47770 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term deposits | 45079 |  | 45079 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate bonds | 15777 |  | 15777 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cash equivalents | 350070 | 77855 | 272215 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Short-term investments:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercial paper | 219355 |  | 219355 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate bonds | 60306 |  | 60306 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. Treasury and agency obligations | 27348 |  | 27348 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term deposits | 3048 |  | 3048 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total short-term investments | 310057 |  | 310057 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total** | $660127 | $77855 | $582272 | $— |

---

------

<u>[**Table of Contents**](#i16ef846430f9402292f85303557ea7bd_7)</u>

**IPG PHOTONICS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)**

**(In thousands, except share and per share data)**

There were no impairments for the investments considered held-to-maturity during the quarters ended September 30, 2025 and 2024. There were no current expected credit loss allowances for the investments considered held-to-maturity at September 30, 2025 and 2024. The Company holds highly-rated held-to-maturity instruments that are within five years of maturity.

The Company did not have any allowance for credit losses other than the allowance for uncollectible accounts receivable. As of September 30, 2025 and December 31, 2024, the allowance for credit losses on trade receivables was $2,565 and $2,462, respectively.

The following table presents the effective maturity dates of debt investments, which are held-to-maturity:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **September 30, 2025** | **September 30, 2025** | **December 31, 2024** | **December 31, 2024** |
| | **Book Value** | **Fair Value** | **Book Value** | **Fair Value** |
| **Investment maturity** | | | | |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less than 1 year | $524359 | $524652 | $310152 | $310057 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 - 5 years | 30166 | 30170 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $554525 | $554822 | $310152 | $310057 |

---

**5. INVENTORIES**

Inventories consist of the following:

---

| | | |
|:---|:---|:---|
| | **September 30,**<br>**2025** | **December 31,**<br>**2024** |
| Components and raw materials | $156637 | $150257 |
| Work-in-process | 44116 | 28973 |
| Finished goods | 123181 | 105550 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $323934 | $284780 |

---

The Company recorded inventory provisions totaling $5,705 and $43,408 for the three months ended September 30, 2025 and 2024, respectively, and $23,014 and $70,259 for the nine months ended September 30, 2025 and 2024 respectively. These provisions relate to the recoverability of the value of inventories due to technological changes and excess quantities. For the three and nine months ended September 30, 2024, the Company recorded additional inventory provisions of $29,487 attributed to items previously considered safety stock and items that became technologically obsolete. These provisions are reported as a reduction to components and raw materials, work-in-process and finished goods.

**6. BUSINESS COMBINATION**

During the fourth quarter of 2024, the Company acquired 100% of the shares of Clean-Lasersysteme GmbH ("cleanLASER") a leader in laser cleaning systems for $66,738, net of cash acquired. The purchase price allocations included in the Company's Condensed Consolidated Financial Statements are not complete, pending finalization of a net working capital adjustment to the purchase price in the fourth quarter of 2025.

**7. GOODWILL AND INTANGIBLES**

The following table sets forth the changes in the carrying amount of goodwill:

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** |
| Balance, beginning of period | $67241 | $38540 |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange adjustment | 4409 | (56) |
| Balance, end of period | $71650 | $38484 |

---

------

<u>[**Table of Contents**](#i16ef846430f9402292f85303557ea7bd_7)</u>

**IPG PHOTONICS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)**

**(In thousands, except share and per share data)**

Intangible assets, subject to amortization, consisted of the following:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **September 30, 2025** | **September 30, 2025** | **September 30, 2025** | **September 30, 2025** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| | **Gross Carrying Amount** | **Accumulated<br>Amortization** | **Net <br>Carrying<br>Amount** | **Weighted-**<br>**Average Lives** | **Gross Carrying Amount** | **Accumulated<br>Amortization** | **Net <br>Carrying<br>Amount** | **Weighted-<br>Average Lives** |
| Customer relationships | $64792 | $(34634) | $30158 | 11 years | $62671 | $(29747) | $32924 | 11 years |
| Technology, and Production know-how | 43261 | (25011) | 18250 | 8 years | 40823 | (22891) | 17932 | 8 years |
| Trademark and trade name | 16114 | (12296) | 3818 | 8 years | 15665 | (11145) | 4520 | 8 years |
| Patents | 8034 | (8034) |  | 8 years | 8034 | (8034) |  | 8 years |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $132201 | $(79975) | $52226 |  | $127193 | $(71817) | $55376 |  |

---

Amortization expense for the three months ended September 30, 2025 and 2024 was $2,402 and $1,377, respectively. Amortization expense for the nine months ended September 30, 2025 and 2024 was $7,498 and $4,180, respectively. The estimated future amortization expense for intangible assets for the remainder of 2025 and subsequent years is as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **2025** <sup>(a)</sup> | **2026** | **2027** | **2028** | **2029** | **Thereafter** | **Total** |
| $2302 | $8060 | $7847 | $7473 | $7232 | $19312 | $52226 |

---

<sup>(a)</sup> For the three-month period beginning October 1, 2025.

 **8. OTHER LIABILITIES**

Accrued expenses and other current liabilities consist of the following:

---

| | | |
|:---|:---|:---|
| | **September 30,**<br>**2025** | **December 31,**<br>**2024** |
| Accrued compensation | $79008 | $56568 |
| Contract liabilities | 54893 | 56454 |
| Current portion of accrued warranty | 19110 | 21398 |
| Short-term lease liabilities | 4903 | 4835 |
| Other | 13114 | 12793 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $171028 | $152048 |

---

Other long-term liabilities and deferred income taxes consist of the following:

---

| | | |
|:---|:---|:---|
| | **September 30,**<br>**2025** | **December 31,**<br>**2024** |
| Unrecognized tax benefits | $16387 | $13855 |
| Accrued warranty | 13538 | 12954 |
| Long-term lease liabilities | 12460 | 13124 |
| Deferred income taxes | 11044 | 14206 |
| Other | 9341 | 5635 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $62770 | $59774 |

---

**9. PRODUCT WARRANTIES**

The Company typically provides one to five years parts and service warranties on lasers, laser and non-laser systems, and amplifiers. Most of the Company's sales offices provide support to customers in their respective geographic areas. Warranty reserves have generally been sufficient to cover product warranty repair and replacement costs.

------

<u>[**Table of Contents**](#i16ef846430f9402292f85303557ea7bd_7)</u>

**IPG PHOTONICS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)**

**(In thousands, except share and per share data)**

Activity related to the warranty accrual was as follows:

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** |
| Balance, beginning of period | $34352 | $47209 |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for warranty accrual | 7807 | 4603 |
| &nbsp;&nbsp;&nbsp;&nbsp;Warranty claims | (11946) | (12902) |
| &nbsp;&nbsp;&nbsp;&nbsp;Warranty related to business divested |  | (1603) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation | 2435 | 118 |
| Balance, end of period | $32648 | $37425 |

---

Accrued warranty reported in the accompanying Condensed Consolidated Financial Statements as of September 30, 2025 and December 31, 2024 consist of $19,110 and $21,398 in Accrued expenses and other current liabilities, respectively, and $13,538 and $12,954 in Other long-term liabilities and deferred income taxes, respectively.

**10. FINANCING ARRANGEMENTS**

***Revolving Line of Credit Facilities:***

On June 24, 2025, the Company entered into a new credit agreement with Bank of America, N.A. which matures on June 24, 2030. The credit agreement provides a $200,000 unsecured, revolving credit facility, of which $25,000 may be used for the issuance of letters of credit. The new facility replaced the previous $75,000 U.S. revolving line of credit with a scheduled maturity date of June 30, 2025.

At September 30, 2025, there were no amounts drawn or guarantees issued on the credit facility. At December 31, 2024, there were no amounts drawn on the prior credit facility, and there were $2,103 of guarantees issued, which reduced the amount of the availability under the facility. The remaining availability under the new line was $200,000 at September 30, 2025.

Under the credit agreement, the Company is required to meet certain financial covenants, which are tested quarterly and include an interest coverage ratio and a net leverage ratio. The interest coverage covenant requires the Company maintain a trailing twelve-month ratio of consolidated EBITDA to consolidated interest expense on all obligations that is at least 3.0 times. The net leverage covenant requires the Company maintain a trailing twelve-month ratio, which is the sum of all indebtedness for borrowed money on a consolidated basis, less cash and available marketable securities not classified as long-term investments in the U.S. in excess of $50,000 up to a maximum of $500,000, to consolidated EBITDA that is less than 3.0 times. The Company was in compliance with the financial covenants as of September 30, 2025.

In addition to the financial covenants, the Company's credit agreement contains additional customary events of default, including non-payment of principal, interest or fees, violation of covenants, cross default to certain other indebtedness, invalidity of any loan document, material judgments, bankruptcy and insolvency events and change of control, subject, in certain instances, to cure periods. Upon the occurrence of an event of default, the lenders may elect to declare amounts outstanding under the credit agreement immediately due and payable.

In addition, the Company maintains Euro lines of credit with a total principal amount of €7,400 ($8,685 and $6,751 as of September 30, 2025 and December 31, 2024, respectively), which are available to certain European subsidiaries. At September 30, 2025 and December 31, 2024, there were no amounts drawn on the Euro lines of credit, and there were $3,680 and $1,533, respectively, of guarantees issued against the facilities, which reduces the amount of the availability under the facilities.

Additionally, the Company has lines of credit totaling $22,021 in various countries, which are used for the issuance of letters of credit, guarantees and overdrafts. As of September 30, 2025, the amount drawn was $2,003 and there were $2,179 of guarantees issued against these facilities.

**11. COMMITMENTS AND CONTINGENCIES**

From time to time, the Company may be involved in legal disputes and other proceedings in the ordinary course of its business. These matters may include allegations of infringement of intellectual property, commercial disputes and employment

------

<u>[**Table of Contents**](#i16ef846430f9402292f85303557ea7bd_7)</u>

**IPG PHOTONICS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)**

**(In thousands, except share and per share data)**

matters. As of September 30, 2025 and through the filing date of these Condensed Consolidated Financial Statements, the Company is aware of no ongoing legal proceedings that management estimates could have a material effect on the Company's Condensed Consolidated Financial Statements.

Effective January 1, 2025, the Company is self-insured for employee medical benefits in the United States. The employee medical obligations are managed by a third-party provider and the related liabilities are included in the Condensed Consolidated Financial Statements. To limit the Company's potential liabilities for these risks, the Company purchases insurance from a third party that provides stop-loss protection for medical costs in the United States that exceed $225 per person per annum.

The Company provides product warranties on its lasers, laser and non-laser systems, and amplifiers. Refer to Note 9, **"**Product Warranties" for information related to the Company's warranty accrual.

**12. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)**

Comprehensive income includes charges and credits to equity that are not the result of transactions with stockholders. Included within comprehensive income is the cumulative foreign currency translation adjustments. These adjustments are accumulated within the Condensed Consolidated Statements of Comprehensive Income (Loss).

Total components of accumulated other comprehensive loss were as follows:

---

| | | |
|:---|:---|:---|
| | **Foreign currency translation adjustments and other** | **Total** |
| Balance, July 1, 2025 | $(37240) | $(37240) |
| Other comprehensive loss, net of tax: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustments and other, net of tax benefit of $94 | (1486) | (1486) |
| Total other comprehensive loss | (1486) | (1486) |
| Balance, September 30, 2025 | $(38726) | $(38726) |
| Balance, July 1, 2024 | $(226852) | $(226852) |
| Other comprehensive income, net of tax: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustments and other before reclassification, net of tax expense of $237 | 21451 | 21451 |
| &nbsp;&nbsp;&nbsp;&nbsp;Reclassification of foreign currency translation adjustments related to the divestiture of Russian operations to net loss, net of tax expense of $1,324 | 136670 | 136670 |
| Total other comprehensive income | 158121 | 158121 |
| Balance, September 30, 2024 | $(68731) | $(68731) |

---

------

<u>[**Table of Contents**](#i16ef846430f9402292f85303557ea7bd_7)</u>

**IPG PHOTONICS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)**

**(In thousands, except share and per share data)**

---

| | | |
|:---|:---|:---|
| | **Foreign currency translation adjustments and other** | **Total** |
| Balance, January 1, 2025 | $(119367) | $(119367) |
| Other comprehensive income, net of tax: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustments and other, net of tax expense of $218 | 80641 | 80641 |
| Total other comprehensive income | 80641 | 80641 |
| Balance, September 30, 2025 | $(38726) | $(38726) |
| Balance, January 1, 2024 | $(212530) | $(212530) |
| Other comprehensive income, net of tax: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustments and other before reclassification, net of tax expense of $112 | 7129 | 7129 |
| &nbsp;&nbsp;&nbsp;&nbsp;Reclassification of foreign currency translation adjustments related to the divestiture of Russian operations to net loss, net of tax expense of $1,324 | 136670 | 136670 |
| Total other comprehensive income | 143799 | 143799 |
| Balance, September 30, 2024 | $(68731) | $(68731) |

---

**13. INCOME TAXES**

The Provision for income taxes were $8,191 and $16,714 for the three and nine months ended September 30, 2025, respectively. The Provision for income taxes was a benefit of $8,920 and a tax expense of $5,441, for the three and nine months ended September 30, 2024, respectively. The effective tax rates were 52.3% and 48.4% for the three and nine months ended September 30, 2025, respectively. The effective tax rate was 3.7% for the three months ended September 30, 2024. For the nine months ended September 30, 2024, there was a tax expense provided on the Loss before provision for income taxes.

For the three months ended September 30, 2025, the Company recorded discrete tax items of $3,803 primarily due to uncertain tax positions resulting from tax audit activity. For the nine months ended September 30, 2025, the Company recorded discrete tax items of $8,692, primarily due to equity-based compensation expense reflected in the Company's Condensed Consolidated Financial Statements of Operations in excess of the deductions allowed for tax purposes and uncertain tax positions resulting from audits.

There was a tax detriment for both periods in 2024 related primarily to $41,482 of losses not benefitted from the loss on divestiture of Russian operations, which occurred in the three months ended September 30, 2024. Excluding the divestiture of Russian operations, the other discrete tax items for the three months ended September 30, 2024 did not have a significant effect on the Company's tax rate. Excluding the divestiture of Russian operations, the other discrete tax detriment of $1,435 for the nine months ended September 30, 2024, related primarily to equity-based compensation which was partially offset by a benefit related to reductions of tax reserves.

The Company accounts for its uncertain tax positions in accordance with the accounting standards for income taxes. The Company classifies interest and penalties related to unrecognized tax benefits as a component of the provision for income taxes.

------

<u>[**Table of Contents**](#i16ef846430f9402292f85303557ea7bd_7)</u>

**IPG PHOTONICS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)**

**(In thousands, except share and per share data)**

The following is a summary of the activity of the Company's unrecognized tax benefits for the nine months ended September 30, 2025 and 2024:

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** |
| Balance, beginning of period | $13855 | $17176 |
| &nbsp;&nbsp;Change in prior period positions | 2895 | (3130) |
| &nbsp;&nbsp;Additions for tax positions in current period | 164 | 249 |
| &nbsp;&nbsp;Foreign currency translation | (527) | 94 |
| Balance, end of period | $16387 | $14389 |

---

The liability for uncertain tax benefits is included in Other long-term liabilities and deferred income taxes. Substantially all of the liability for uncertain tax benefits related to various federal, state and foreign income tax matters would benefit the Company's effective tax rate if those tax benefits are recognized.

**14. NET INCOME (LOSS) PER COMMON SHARE**

The following table sets forth the computation of diluted net income (loss) per common share following the treasury stock method:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net income (loss) | $7463 | $(233594) | $17826 | $(189341) |
| Basic weighted average common shares | 42198713 | 43837357 | 42426713 | 44901247 |
| Dilutive effect of common stock equivalents | 357604 |  | 232530 |  |
| Diluted weighted average common shares | 42556317 | 43837357 | 42659243 | 44901247 |
| Basic net income (loss) per common share | $0.18 | $(5.33) | $0.42 | $(4.22) |
| Diluted net income (loss) per common share | $0.18 | $(5.33) | $0.42 | $(4.22) |

---

The computation of diluted weighted average common shares excludes common stock equivalents including non-qualified stock options, performance stock units ("PSUs"), restricted stock units ("RSUs") and employee stock purchase plan ("ESPP") because the effect of including them would be anti-dilutive. The weighted average anti-dilutive shares outstanding for the three and nine months ended September 30, 2025 and 2024 were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Non-qualified stock options | 526624 | 672225 | 550766 | 603058 |
| Restricted stock units | 20727 | 202368 | 346125 | 232622 |
| Performance stock units | 56068 | 87662 | 60212 | 58872 |
| Employee stock purchase plan |  | 10494 |  | 41977 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total weighed average anti-dilutive shares outstanding | 603419 | 972749 | 957103 | 936529 |

---

On February 13, 2024, the Company announced that its Board of Directors has authorized the purchase of up to $300,000 of IPG common stock. This authorization is in addition to the Company's previously authorized stock repurchase programs.

For the three and nine months ended September 30, 2025, the Company repurchased 214,408 and 705,390 shares under the February 2024 authorization, with a weighted average price of $75.99 and $65.63 per share in the open market, respectively. For the three and nine months ended September 30, 2024, the Company repurchased 984,060 and 3,346,234 shares with a weighted average price of $74.90 and $84.79 per share in the open market, respectively. The impact on the reduction of weighted average shares for the three and nine months ended September 30, 2025 was 133,128 and 298,476 shares, respectively. The impact for the three and nine months ended September 30, 2024 was 391,942 and 1,607,958 shares, respectively. As of September 30, 2025, the Company had $3,708 remaining under the February 2024 authorization.

------

<u>[**Table of Contents**](#i16ef846430f9402292f85303557ea7bd_7)</u>

**IPG PHOTONICS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)**

**(In thousands, except share and per share data)**

**15. SEGMENT REPORTING**

The Company operates in one segment which involves the design, development, production and distribution of fiber lasers, laser and non-laser systems, fiber amplifiers, and related optical components. The Company has a single, company-wide management team that administers the enterprise as a whole rather than as discrete operating segments. The chief operating decision maker ("CODM"), who is the Company's chief executive officer, also measures financial performance as a single enterprise, and not on geography, legal entity, or end market basis. Throughout the year, the CODM allocates capital resources on a project-by-project basis across the Company's entire asset base, as reflected in the Company's Condensed Consolidated Balance Sheets, to maximize profitability without regard to geography, legal entity, or end market basis. The Company operates in a number of countries throughout the world in a variety of product lines. Information regarding product lines and geographic financial information is provided in Note 3, "Revenue from Contracts with Customers."

The CODM primarily utilizes "Net income (loss)," as well as "Net income (loss) per common share" included in the Company's Condensed Consolidated Statements of Operations as the key indicators in assessing the enterprise's performance and allocating resources. In evaluating Net income (loss), the CODM also reviews gross profit as well the Company's income (loss) before foreign exchange and other segment items to set and evaluate performance targets.

The following table presents the break-down of Net income (loss), including significant segment expenses.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| | **(In thousands, except per share data)** | **(In thousands, except per share data)** | **(In thousands, except per share data)** | |
| Net sales | $250792 | $233143 | $729306 | $742797 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of product sold and other expenses <sup>(a)</sup> | 122488 | 139565 | 350016 | 371510 |
| &nbsp;&nbsp;&nbsp;&nbsp;Manufacturing, service and other operations salaries, bonus, and benefits, including contractor costs | 72953 | 61655 | 211273 | 200793 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other manufacturing expenses <sup>(b)</sup> | 33573 | 31105 | 94318 | 97802 |
| &nbsp;&nbsp;&nbsp;&nbsp;Capitalized labor and overhead | (77227) | (53271) | (208691) | (175119) |
| Cost of sales | 151787 | 179054 | 446916 | 494986 |
| Gross profit | 99005 | 54089 | 282390 | 247811 |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing, research and development and general and administrative <sup>(c)</sup> | 89221 | 82070 | 265166 | 247183 |
| Income (loss) before foreign exchange and other segment items | 9784 | (27981) | 17224 | 628 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on foreign exchange | (1504) | (1148) | (7013) | (6067) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income, net | 7283 | 11103 | 22728 | 38058 |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for income taxes | (8191) | 8920 | (16714) | (5441) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other segment items <sup>(d)</sup> | 91 | (224488) | 1601 | (216519) |
| Net income (loss) | $7463 | $(233594) | $17826 | $(189341) |

---

<sup>(a)</sup> Includes cost of materials, labor and overhead, shipping costs, scrap, and inventory reserves.

<sup>(b)</sup> Includes depreciation and amortization, service, warranty, and other manufacturing expenses.

<sup>(c)</sup> Sales and marketing, research and development and general and administrative expenses are disclosed by period in the Company's Condensed Consolidated Statements of Operations.

<sup>(d)</sup> Other segment items include net loss from divestiture and sale of assets, impairment of long-lived assets, restructuring charges and other income (expense), net.

------

<u>[Table](#i16ef846430f9402292f85303557ea7bd_7)[of Contents](#i16ef846430f9402292f85303557ea7bd_7)</u>

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS** 

*You should read the following discussion in conjunction with our Condensed Consolidated Financial Statements and related notes included elsewhere in this Quarterly Report on Form 10-Q. This discussion contains forward looking statements that are based on management's current expectations, estimates and projections about our business and operations. Our actual results may differ materially from those currently anticipated and expressed in such forward-looking statements. See "Cautionary Statement Regarding Forward-Looking Statements."*

**Overview**

We develop, manufacture and sell high-performance fiber lasers and diode lasers that are used for diverse applications, primarily in materials processing. We also manufacture and sell complementary products used with our lasers including optical delivery cables, fiber couplers, beam switches, optical processing heads, in-line sensors and chillers. In addition, we offer laser-based and non-laser based systems for certain markets and applications. Our portfolio of laser solutions is used in materials processing, medical, and advanced applications. We sell our products globally to original equipment manufacturers ("OEMs"), system integrators and end users. We market our products internationally, primarily through our direct sales force. Our major manufacturing facilities are located in the United States and Germany. In response to the risks from the Russia-Ukraine conflict, we expanded our manufacturing operations in Germany, the United States and Italy, and have added manufacturing capacity in Poland to meet the demand for our products and our sales and support needs. In addition, we have ceased new investment in our Belarusian operations and have outsourced the supply laser cabinets and mechanical components that were supplied by that operation. We have sales and service offices and applications laboratories worldwide.

We are vertically integrated such that we design and manufacture most of the key components used in our finished products, from semiconductor diodes to optical fiber preforms, finished fiber lasers and complementary products. Our vertically integrated operations allow us to reduce manufacturing costs, control quality, rapidly develop and integrate advanced products and protect our proprietary technology.

**Factors and Trends That Affect Our Operations and Financial Results** 

In reading our financial statements, you should be aware of the following factors and trends that our management believes are important in understanding our financial performance.

*Recently announced U.S. Government Tariffs.* We continue to closely monitor changes in international trade relations and economic and monetary policies, including recently announced tariffs on imports into the U.S. from China, Germany and other countries, as well as retaliatory tariffs in affected countries, which could adversely impact the global economy and our operating results. The impact to gross margin related to higher tariffs for the three and nine months ended September 30, 2025 was approximately 140 and 90 basis points, respectively, as compared to the three and nine months ended September 30, 2024.

*Belarusian Operations.* We manufacture laser cabinets and other mechanical components in Belarus. In response to the Russia-Ukraine conflict, the EU issued additional sanctions impacting commerce with Belarus on June 29, 2024, which restricted the supply of laser cabinets and other mechanical components from our factory in Belarus to our Germany operations after October 2, 2024. As a result of the sanctions and their impact on our Belarusian operations, we completed an impairment analysis of our Belarus assets during the third quarter of 2024 and recorded $26.6 million of impairment of long-lived asset in our Condensed Consolidated Statements of Operations. At September 30, 2025, the remaining value of the long-lived assets in Belarus was $4.2 million. Net working capital deficit excluding cash was $0.4 million and cash on hand was $0.7 million. The net asset value of our Belarus subsidiary has been reduced by $17.6 million due to the cumulative translation effect of the Belarusian ruble compared to the U.S. dollar, which is included in the accumulated other comprehensive loss component of stockholders' equity. We may incur additional asset impairment charges related to the Belarusian operations and the other comprehensive loss that is currently in the equity section of our Condensed Consolidated Balance Sheets could be charged to our Condensed Consolidated Statements of Operations.

We continue to review our operations in Belarus including potential strategic alternatives. We have qualified third party vendors to supply components previously supplied from Belarus and have begun purchasing from them. Our Board of Directors monitors and continues to assess risks associated with our Belarusian operations.

*Net sales.* Our net sales have historically fluctuated from quarter to quarter. The increase or decrease in sales from a prior quarter can be affected by the timing of orders received from customers, the timing of shipments, the mix of OEM orders and one-time orders for products with large purchase prices, competitive pressures, acquisitions, economic and political conditions in a certain country or region and seasonal factors such as the purchasing patterns and levels of activity throughout the year in the regions where we operate. Net sales can be affected by the time taken to qualify our products for use in new applications in

------

<u>[Table](#i16ef846430f9402292f85303557ea7bd_7)[of Contents](#i16ef846430f9402292f85303557ea7bd_7)</u>

the end markets that we serve. Our sales cycle varies substantially, ranging from a period of a few weeks to as long as one year or more, but is typically several months. The adoption of our products by a new customer or qualification in a new application can lead to an increase in net sales for a period, which may then slow until we penetrate new markets or obtain new customers. Foreign exchange rates also affect our net sales, due to changes in the U.S. dollar value of sales made in foreign currencies.

Our business depends substantially upon capital expenditures by end users, particularly by manufacturers using our products for materials processing, which includes general manufacturing, automotive including electric vehicles ("EV"), other transportation, aerospace, heavy industry, consumer, semiconductor and electronics. Approximately 86% of our revenues for the first three quarters of 2025, and 88% for the full fiscal year of 2024 were from customers using our products for materials processing. Although applications within materials processing are broad, the capital equipment market in general is cyclical and historically has experienced sudden and severe downturns. For the foreseeable future, our operations will continue to depend upon capital expenditures by end users of materials processing equipment and will be subject to the broader fluctuations of capital equipment spending.

In recent years, our net sales and margins have been negatively impacted by tariffs and trade policy. New tariffs and other changes in U.S. trade policy could trigger retaliatory actions by affected countries, and certain foreign governments. We are also susceptible to global or regional disruptions such as political instability, geopolitical conflicts, acts of terrorism, significant fluctuations in currency values, natural disasters and pandemics to the extent that they affect macroeconomic conditions, global supply chains or individual IPG locations.

The average selling prices of our products generally decrease as the products mature. These decreases result from factors such as increased competition, decreased manufacturing costs and increased unit volumes. We may also reduce selling prices in order to penetrate new markets and applications. Furthermore, we may negotiate discounted selling prices from time to time with certain customers that place high unit-volume orders.

The secular shift to fiber laser technology in large materials processing applications, such as welding and cutting applications, had a positive effect on our sales trends in the past such that our sales trends were often better than other capital equipment manufacturers in both positive and negative economic cycles. As the secular shift to fiber laser technology matures in such applications, our sales trends are more susceptible to economic cycles, which can broadly affect the demand for capital equipment including machine tools and industrial lasers, and competition from other fiber laser manufacturers. Additionally, as our technology matures, we become subject to more competition which can affect sales trends.

*Gross margin.* Our total gross margin in any period can be significantly affected by a number of factors, including net sales, production volumes, competitive factors, product mix, and by other factors such as changes in foreign exchange rates relative to the U.S. dollar, tariffs and shipping costs. Many of these factors are not under our control. The following are examples of factors affecting gross margin:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• As our products mature, we can experience additional competition which tends to decrease average selling prices and affects gross margin;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our gross margin can be significantly affected by product mix. Within each of our product categories, the gross margin is generally higher for devices with greater average power. These higher power products often have better performance, more difficult specifications to attain and fewer competing products in the marketplace;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Higher power lasers also use a greater number of optical components, improving absorption of fixed overhead costs and enabling economies of scale in manufacturing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The gross margin for certain specialty products may be higher because there are fewer or sometimes no equivalent competing products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Customers that purchase devices in greater unit volumes generally are provided lower prices per device than customers that purchase fewer units. In general, lower selling prices to high unit volume customers reduce gross margin although this may be partially offset by improved absorption of fixed overhead costs associated with larger product volumes, which drive economies of scale;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Gross margin on systems can be lower than gross margin for our lasers and sub-systems, depending on the configuration, volume and competitive forces, among other factors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Persistent inflation leading to increases in average manufacturing salaries as well as an increase in the purchase price of components including, but not limited to, electronic components and metal parts could negatively impact gross margin if we are not able to pass those increases on to customers by increasing the selling price of our products;

------

<u>[Table](#i16ef846430f9402292f85303557ea7bd_7)[of Contents](#i16ef846430f9402292f85303557ea7bd_7)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Changes in relative exchange rates between currencies we receive when selling our products and currencies we use to pay our manufacturing expenses; and finally,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our gross margin from products on new manufacturing lines can be lower due to production inefficiencies and high scrap costs.

We expect that some new technologies, products and systems will have returns above our cost of capital but may have gross margins below our corporate average. If we are able to develop opportunities that are significant in size, competitively advantageous or leverage our existing technology base and leadership, our current gross margin levels may not be maintained. Instead, we aim to deliver industry-leading levels of gross margins by growing sales, by taking market share in existing markets, or by developing new applications and markets we address, by reducing the cost of our products and by optimizing the efficiency of our manufacturing operations.

A high proportion of our costs is fixed so costs are generally difficult to adjust or may take time to adjust in response to changes in demand. In addition, our fixed costs increase as we expand our capacity. If we expand capacity faster than is required by sales growth, gross margins could be negatively affected. Gross margins generally decline if production volumes are lower as a result of a decrease in sales or a reduction in inventory because the absorption of fixed manufacturing costs will be reduced. Gross margins generally improve when the opposite occurs. If both sales and inventory decrease in the same period, the decline in gross margin may be greater if we cannot reduce fixed costs or choose not to reduce fixed costs to match the decrease in the level of production. If we experience a decline in sales that reduces absorption of our fixed costs, or if we have production issues, our gross margins will be negatively affected.

We also regularly review our inventory for items that are slow-moving, have been rendered obsolete or are determined to be excess. Any provision for such slow-moving, obsolete or excess inventory affects our gross margins. For example, we recorded provisions for slow-moving, obsolete or excess inventory totaling $5.7 million and $43.4 million for the three months ended September 30, 2025 and 2024, respectively and $23.0 million and $70.3 million for the nine months ended September 30, 2025 and 2024, respectively. For the three months ended September 30, 2024, we recorded additional inventory provisions of $29.5 million attributed to items previously considered safety stock and items that became technologically obsolete.

*Selling and general and administrative expenses.* In the past, we invested in selling and general and administrative costs in order to support continued growth in the Company. As the secular shift to fiber laser technology matures, our sales growth becomes more susceptible to the cyclical trends typical of capital equipment manufacturers. Accordingly, our future management of and investments in selling and general and administrative expenses will also be influenced by these trends, although we may still invest in selling or general and administrative functions to support certain initiatives even in economic down cycles. Certain general and administrative expenses are not related to the level of sales and may vary quarter to quarter based primarily upon the level of acquisitions, litigation and project-related consulting expenses. Additionally, selling and general and administrative expenses will also be influenced by accruals for variable compensation and performance stock unit expense both of which are dependent upon our performance relative to preestablished targets.

*Research and development expenses.* We plan to continue to invest in research and development to improve our existing components and products and develop new components, products, systems and applications technology. We believe that these investments will sustain our position as a leader in the fiber laser industry and will support development of new products that can address new markets and growth opportunities. The amount of research and development expense we incur may vary from period to period.

In 2025, we increased spending in multiple areas to support our strategic initiatives and growth. Operating expenses rose as we hired additional executives and managers to strengthen management capabilities. We also invested in several key areas, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• software enhancements to improve the seamless integration of products and components to drive their ease of use and functionality;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• component and product cost reductions to improve profitability;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• new product development for medical, advanced and micromachining; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• sales and marketing to better service our customers, improve the customer experience and our new product introductions.

To set the foundation for growth, we expect such spending to remain at current or at increased levels.

------

<u>[Table](#i16ef846430f9402292f85303557ea7bd_7)[of Contents](#i16ef846430f9402292f85303557ea7bd_7)</u>

*Goodwill and long-lived assets impairments*. We review our intangible assets and property, plant and equipment for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. Goodwill is required to be tested for impairment at least annually. Negative industry or economic trends, including reduced estimates of future cash flows, disruptions to our business, slower growth rates, lack of growth in our relevant business units, differences in the estimated product acceptance rates, or market prices below the carrying value of long-lived assets evaluated for sale could lead to impairment charges against our long-lived assets, including goodwill and other intangible assets.

Our valuation methodology for assessing impairment requires management to make significant judgments and assumptions based on historical experience and to rely heavily on projections of future operating performance and future strategic use of our asset footprint. Also, the process of evaluating the potential impairment of goodwill is subjective. We operate in a highly competitive environment and projections of future operating results, asset usage and cash flows may vary significantly from actual results. If our analysis indicates potential impairment to goodwill in one or more of our reporting units, we may be required to record charges to earnings in our financial statements, which could negatively affect our results of operations.

*Foreign exchange.* Because we are a U.S.-based company doing business globally, we have both translational and transactional exposure to fluctuations in foreign currency exchange rates. Changes in the relative exchange rate between the U.S. dollar and the foreign currencies in which our subsidiaries operate directly affects our sales, costs and earnings. Differences in the relative exchange rates between where we sell our products and where we incur manufacturing and other operating costs (primarily in the U.S. and Germany) also affects our costs and earnings. Certain currencies experiencing significant exchange rate fluctuations like the euro, the Chinese yuan and Japanese yen have had and could have an additional significant impact on our sales, costs and earnings. For the quarter ended September 30, 2025, the foreign exchange loss was primarily attributable to the depreciation of the Korean won and Indian rupee as compared to the U.S. dollar. Our Korean and Indian subsidiaries both have certain net liabilities denominated in U.S. dollars. Our ability to adjust the foreign currency selling prices of products in response to changes in exchange rates is limited and may not offset the impact of the changes in exchange rates on the translated value of sales or costs. In addition, if we increase the selling price of our products in local currencies, this could have a negative impact on the demand for our products.

Income taxes. On December 15, 2022, the European Union (EU) Member States formally adopted the EU's Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development ("OECD") Pillar Two Framework that was supported by over 130 countries worldwide. The EU effective dates were January 1, 2024, and January 1, 2025, for different aspects of the directive. The impact of the Pillar Two Framework on our income tax provision for the nine months ended September 30, 2025 was not material. We are continuing to evaluate the potential impact of the Pillar Two Framework on future periods, pending legislative adoption by additional individual countries.

On July 4, 2025, the U.S. enacted H.R. 1 "A bill to provide for reconciliation pursuant to Title II of H. Con. Res. 14", commonly referred to as the One Big Beautiful Bill Act ("OBBBA"). OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the 2017 Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. Changes in tax laws may affect recorded deferred tax assets and deferred tax liabilities and our effective tax rate in the future. The legislation does not have a material impact on our financial statements.

*Major customers.* While we have historically depended on a few customers for a large percentage of our annual net sales, the composition of this group can change from period to period. Net sales derived from our five largest customers as a percentage of our net sales was 15% for the nine months ended September 30, 2025 and 13% for the full years ended December 31, 2024 and 2023, respectively. One of our customers accounted for 13% and 12% of our net accounts receivable as of September 30, 2025 and December 31, 2024, respectively. We seek to add new customers and to expand our relationships with existing customers. We anticipate that the composition of our significant customers will continue to change. We generally do not enter into agreements with our customers obligating them to purchase a fixed number or large volume of our products. If any of our significant customers substantially reduced their purchases from us, our results would be adversely affected.

**Results of Operations for the Three Months Ended September 30, 2025 Compared to the Three Months Ended September 30, 2024**

*Net sales.* Net sales increased by $17.7 million, or 7.6%, to $250.8 million for the three months ended September 30, 2025 from $233.1 million for the three months ended September 30, 2024.

------

<u>[Table](#i16ef846430f9402292f85303557ea7bd_7)[of Contents](#i16ef846430f9402292f85303557ea7bd_7)</u>

The table below sets forth sales by application:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | | |
| | **2025** | **2025** | **2024** | **2024** | **Change** | **Change** |
| | **(In thousands, except for percentages)** | **(In thousands, except for percentages)** | **(In thousands, except for percentages)** | **(In thousands, except for percentages)** | | |
| **<u>Sales by Application</u>** |  | **% of Total** |  | **% of Total** |  |  |
| Materials processing | $219427 | 87.5% | $207063 | 88.8% | $12364 | 6.0% |
| Other applications | 31365 | 12.5% | 26080 | 11.2% | 5285 | 20.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $250792 | 100.0% | $233143 | 100.0% | $17649 | 7.6% |

---

The table below sets forth sales by type of product and other revenue:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | | |
| | **2025** | **2025** | **2024** | **2024** | **Change** | **Change** |
| | **(In thousands, except for percentages)** | **(In thousands, except for percentages)** | **(In thousands, except for percentages)** | **(In thousands, except for percentages)** | | |
| **<u>Sales by Product</u>** |  | **% of Total** |  | **% of Total** |  |  |
| High Power Continuous Wave ("CW") Lasers | $76553 | 30.5% | $81325 | 34.9% | $(4772) | (5.9)% |
| Medium Power CW Lasers | 21135 | 8.4% | 15110 | 6.5% | 6025 | 39.9% |
| Pulsed Lasers | 34159 | 13.6% | 33470 | 14.3% | 689 | 2.1% |
| Quasi-Continuous Wave ("QCW") Lasers | 14771 | 5.9% | 10180 | 4.4% | 4591 | 45.1% |
| Laser and Non-Laser Systems | 35590 | 14.2% | 35265 | 15.1% | 325 | 0.9% |
| Other Revenue including Other Lasers, Amplifiers, Service, Parts, and Accessories | 68584 | 27.4% | 57793 | 24.8% | 10791 | 18.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $250792 | 100.0% | $233143 | 100.0% | $17649 | 7.6% |

---

Materials processing sales accounted for 87.5% of total revenue and increased 6.0% year over year, as a result of higher sales in welding, additive manufacturing applications, cleaning, and micromachining, partially offset by lower sales in marking. Other applications sales increased 20.3% year over year driven by higher revenue in medical procedures and advanced applications.

*Cost of sales and gross margin.* Cost of sales decreased by $27.3 million, or 15.2%, to $151.8 million for the three months ended September 30, 2025 from $179.1 million for the three months ended September 30, 2024. The prior year costs of sales included additional inventory provisions of $29.5 million attributed to items previously considered safety stock and items that became technologically obsolete. Our gross margin increased to 39.5% for the three months ended September 30, 2025 from 23.2% for the three months ended September 30, 2024. Additionally, the increase in gross margin was due to a decrease in unabsorbed manufacturing costs of $10.2 million and cost of product sold of $17.1 million, primarily due to lower inventory provisions, partially offset by higher product costs due to product and geographic mix, and import duties driven by tariffs, as a percentage of sales.

*Sales and marketing expense.* Sales and marketing expense increased by $1.6 million, or 7.2%, to $23.8 million for the three months ended September 30, 2025 from $22.2 million for the three months ended September 30, 2024. This change was primarily the result of an increase of $0.8 million in amortization expense, an increase of $0.8 million in personnel and related expenses, and an increase of $0.7 million in costs related to trade fairs and exhibits, partially offset by a decrease of $0.6 million in premises expense. As a percentage of sales, sales and marketing expense was 9.5% for both the three months ended September 30, 2025 and 2024, respectively.

*Research and development expense.* Research and development expense increased by $3.2 million, or 11.8%, to $30.4 million for the three months ended September 30, 2025, compared to $27.2 million for the three months ended September 30, 2024. This change was primarily the result of an increase of $1.8 million in consultant fees, an increase of $0.9 million in personnel and related expenses, and an increase of $0.6 million in materials expense. As a percentage of sales, research and development expense increased to 12.1% from 11.7% for the three months ended September 30, 2025 and 2024, respectively.

*General and administrative expense.* General and administrative expense increased by $2.4 million, or 7.3%, to $35.1 million for the three months ended September 30, 2025 from $32.7 million for the three months ended September 30, 2024. The change was primarily the result of an increase of $3.9 million in personnel and related expenses, partially offset by a decrease of $0.8 million in bad debt expense, and a decrease of $0.4 million in premises expense. As a percentage of sales, general and administrative expense was 14.0% for both the three months ended September 30, 2025 and 2024, respectively.

------

<u>[Table](#i16ef846430f9402292f85303557ea7bd_7)[of Contents](#i16ef846430f9402292f85303557ea7bd_7)</u>

*Net loss from divestiture and sale of assets*. During the three months ended September 30, 2024, we divested our Russian operations for $51.1 million. The divestiture resulted in a loss of $197.7 million. There were no divestitures or sale of assets during the three months ended September 30, 2025.

*Impairment of long-lived assets.* During the three months ended September 30, 2024, we completed an impairment analysis of the assets in Belarus as a result of new EU sanctions that would limit our ability to supply laser cabinets and other mechanical components from our factory in Belarus. Based on this analysis, we recorded $26.6 million of impairment of long-lived assets. There was no impairment during the three months ended September 30, 2025.

*Restructuring charges.* We incurred $0.4 million in restructuring charges during the three months ended September 30, 2025, related to an assessment and further oversight of our Belarusian operations. There were no restructuring charges during the three months ended September 30, 2024.

*Effect of exchange rates on net sales, gross profit and operating expenses.* If exchange rates relative to the U.S. dollar had been the same as the comparable quarter one year ago, which were on average euro 0.91, Japanese yen 149 and Chinese yuan 7.16, respectively, we estimate that net sales for the three months ended September 30, 2025 would have been $3.4 million lower, gross profit would have been $1.1 million lower and total sales and marketing, research and development, and general and administrative expenses would have been $1.1 million lower.

*Loss on foreign exchange.* We incurred a foreign exchange transaction loss of $1.5 million for the three months ended September 30, 2025 as compared to a $1.1 million loss for the three months ended September 30, 2024. Our Indian and South Korean subsidiaries both have certain net liabilities denominated in U.S. dollars. The foreign exchange loss for the three months ended September 30, 2025 was primarily attributable to the depreciation of the South Korean won and Indian rupee as compared to the U.S. dollar.

*Interest income, net.* Interest income, net was $7.3 million for the three months ended September 30, 2025 as compared to $11.1 million of income for three months ended September 30, 2024. The change in interest income, net was due to a reduction in total cash and investments, lower weighted average interest rates across our investment portfolio and geographic mix in the current period as compared to the prior year.

*Provision for income taxes*. The provision for income taxes was an expense and benefit of $8.2 million and $8.9 million, for the three months ended September 30, 2025 and 2024, respectively. The effective tax rate was 52.3% for the three months ended September 30, 2025. This compares to the effective tax rate for the three months ended September 30, 2024 of 3.7%. The increase in tax expense in 2025 was primarily due to higher income before provision for income taxes for the three months ended September 30, 2025, as compared to the three months ended September 30, 2024. There was a net tax detriment in the three months ended September 30, 2025 of $3.8 million primarily due to increases in uncertain tax positions resulting from tax audit activity. This compares to a net discrete tax detriment of $41.5 million for the three months ended September 30, 2024, which is primarily related to losses on the divestiture of Russian operations. The other discrete items for the three months ended September 30, 2024 did not have a significant impact on our tax rate.

*Net income (loss).* Net income (loss) increased by $241.1 million to a net income of $7.5 million for the three months ended September 30, 2025 compared to a net loss of $233.6 million for the three months ended September 30, 2024 due to the factors described above.

**Results of Operations for the Nine Months Ended September 30, 2025 Compared to the Nine Months Ended September 30, 2024** 

*Net sales.* Net sales decreased by $13.5 million, or 1.8% to $729.3 million for the nine months ended September 30, 2025 from $742.8 million for the nine months ended September 30, 2024.

The table below sets forth sales by application:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | | |
| | **2025** | **2025** | **2024** | **2024** | **Change** | **Change** |
| | **(In thousands, except for percentages)** | **(In thousands, except for percentages)** | **(In thousands, except for percentages)** | **(In thousands, except for percentages)** | | |
| **<u>Sales by Application</u>** |  | **% of Total** |  | **% of Total** |  |  |
| Materials processing | $627397 | 86.0% | $659201 | 88.7% | $(31804) | (4.8)% |
| Other applications | 101909 | 14.0% | 83596 | 11.3% | 18313 | 21.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $729306 | 100.0% | $742797 | 100.0% | $(13491) | (1.8)% |

---

------

<u>[Table](#i16ef846430f9402292f85303557ea7bd_7)[of Contents](#i16ef846430f9402292f85303557ea7bd_7)</u>

The table below sets forth sales by type of product and other revenue:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | | |
| | **2025** | **2025** | **2024** | **2024** | **Change** | **Change** |
| | **(In thousands, except for percentages)** | **(In thousands, except for percentages)** | **(In thousands, except for percentages)** | **(In thousands, except for percentages)** | | |
| **<u>Sales by Product</u>** |  | **% of Total** |  | **% of Total** |  |  |
| High Power CW Lasers | $222121 | 30.5% | $254343 | 34.2% | $(32222) | (12.7)% |
| Medium Power CW Lasers | 66274 | 9.1% | 47082 | 6.3% | 19192 | 40.8% |
| Pulsed Lasers | 108793 | 14.9% | 110825 | 14.9% | (2032) | (1.8)% |
| QCW Lasers | 37300 | 5.1% | 36520 | 4.9% | 780 | 2.1% |
| Laser and Non-Laser Systems | 108398 | 14.9% | 111436 | 15.0% | (3038) | (2.7)% |
| Other Revenue including Amplifiers, Service, Parts, Accessories and Change in Deferred Revenue | 186420 | 25.5% | 182591 | 24.7% | 3829 | 2.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $729306 | 100.0% | $742797 | 100.0% | $(13491) | (1.8)% |

---

Materials processing sales accounted for 86.0% of total revenue and decreased 4.8% year over year, as a result of lower sales in cutting, welding, and marking applications, partially offset by higher revenue in cleaning, additive manufacturing, and micromachining. Other applications sales increased 21.9% year over year driven by higher revenue in medical procedures and advanced applications.

*Cost of sales and gross margin.* Cost of sales decreased by $48.1 million, or 9.7%, to $446.9 million for the nine months ended September 30, 2025 from $495.0 million for the nine months ended September 30, 2024. The prior year costs of sales included additional inventory provisions of $29.5 million attributed to items previously considered safety stock and items that became technologically obsolete. Our gross margin increased to 38.7% for the nine months ended September 30, 2025 from 33.4% for the nine months ended September 30, 2024. Additionally, the increase in gross margin was due to a decrease in unabsorbed manufacturing costs of $26.6 million and cost of products sold of $21.5 million, primarily due to lower inventory provisions, partially offset by higher product costs due to product and geographic mix, and import duties driven by tariffs, as a percentage of sales.

*Sales and marketing expense.* Sales and marketing expense increased by $6.1 million, or 9.0%, to $73.8 million for the nine months ended September 30, 2025 compared with $67.7 million for the nine months ended September 30, 2024. This change was primarily the result of an increase of $4.0 million in personnel and related expenses, and an increase of $2.8 million in amortization expense, partially offset by a decrease of $1.0 million in premises expenses. As a percentage of sales, sales and marketing expense increased to 10.1% from 9.1% for the nine months ended September 30, 2025 and 2024, respectively.

*Research and development expense.* Research and development expense increased by $4.6 million, or 5.5%, to $88.6 million for the nine months ended September 30, 2025, compared to $84.0 million for the nine months ended September 30, 2024. This change was primarily the result of an increase of $3.4 million in personnel and related expenses, and an increase of $2.4 million in consultant fees, partially offset by a decrease of $0.7 million in lease expense. As a percentage of sales, research and development expense increased to 12.2% from 11.3% for the nine months ended September 30, 2025 and 2024, respectively.

*General and administrative expense.* General and administrative expense increased by $7.4 million, or 7.8%, to $102.8 million for the nine months ended September 30, 2025 from $95.4 million for the nine months ended September 30, 2024. This change was primarily the result of an increase of $10.5 million in personnel and related expenses, and an increase of $0.5 million in information systems costs, partially offset by a decrease of $1.1 million in premises expenses, a decrease of $0.9 million in legal expense, and a decrease of $0.8 million in bad debt expense. As a percentage of sales, general and administrative expense increased to 14.1% from 12.8% for the nine months ended September 30, 2025 and 2024, respectively.

*Net loss from divestiture and sale of assets*. During the nine months ended September 30, 2024 we incurred a net loss from divestiture and sale of assets of $190.2 million. The loss was primarily related to the divestiture of our Russian operations for $197.7 million, partially offset by a gain on sale of assets of $7.5 million related to the sales of a building and land in the U.S. and a building in the U.K. There were no divestitures or sale of assets during the nine months ended September 30, 2025.

*Impairment of long-lived assets*. During the nine months ended September 30, 2024, we completed an impairment analysis of the assets in Belarus as a result of new EU sanctions that would limit our ability to supply laser cabinets and other

------

<u>[Table](#i16ef846430f9402292f85303557ea7bd_7)[of Contents](#i16ef846430f9402292f85303557ea7bd_7)</u>

mechanical components from our factory in Belarus. Based on this analysis, we recorded $26.6 million of impairment of long-lived assets. There was no impairment during the nine months ended September 30, 2025.

*Restructuring charges.* We incurred $0.4 million in restructuring charges during the nine months ended September 30, 2025, related to an assessment and further oversight of our Belarusian operations. There were no restructuring charges during the nine months ended September 30, 2024.

*Effect of exchange rates on net sales, gross profit and operating expenses.* We estimate that, if exchange rates relative to the U.S. dollar had been the same as the comparable nine-month period one year ago, which were on average euro 0.92, Japanese yen 151 and Chinese yuan 7.19, respectively, we would have expected net sales for the nine months ended September 30, 2025 to be $2.3 million lower, gross profit to be $0.5 million lower and total sales and marketing, research and development, and general and administrative expenses would have been $0.9 million lower.

*Loss on foreign exchange.* We incurred a foreign exchange transaction loss of $7.0 million for the nine months ended September 30, 2025 as compared to a loss of $6.1 million for the nine months ended September 30, 2024. Our European subsidiaries have certain net assets denominated in U.S. dollars, and our Chinese and Indian subsidiaries have certain net liabilities denominated in U.S. dollars. The loss for the nine months ended September 30, 2025 was primarily attributable to loss from the appreciation of the euro as compared to the U.S. dollar, and loss from the depreciation of the Chinese yuan and Indian rupee as compared to the U.S. Dollar.

*Interest income, net*. Interest income, net, was $22.7 million for the nine months ended September 30, 2025 as compared to $38.1 million of income for the nine months ended September 30, 2024. The change in interest income, net was due to a reduction in total cash and investments, lower weighted average interest rates across our investment portfolio and geographic mix in the current period as compared to the prior year.

*Provision for income taxes.* Provision for income taxes was $16.7 million for the nine months ended September 30, 2025 compared to $5.4 million for the nine months ended September 30, 2024. The effective tax rate was 48.4% for the nine months ended September 30, 2025. There was a tax expense provided on Loss before income taxes for the nine months ended September 2024. In 2024, there was a tax detriment primarily related to $41.5 million of losses not benefitted from the loss on divestiture of Russian operations. Excluding the divestiture, the increase in tax expense in 2025 was driven by higher income before provision for income taxes as well as an increase in discrete tax items of $7.3 million primarily due to increases in uncertain tax positions resulting from tax audit activity, compared to the same period in 2024.

The discrete tax detriment of $8.7 million for the nine months ended September 30, 2025, relates primarily to equity-based compensation expense reflected in financial statement income in excess of the deductions allowed for tax purposes and increases in uncertain tax positions due to tax audit activity in the period. This compares to a net discrete tax detriment of $41.5 million for the nine month period ended September 30, 2024, which is primarily related to losses on the divestiture of Russian operations.

*Net income (loss).* Net income (loss) increased by $207.1 million to a net income of $17.8 million for the nine months ended September 30, 2025 compared to a net loss of $189.3 million for the nine months ended September 30, 2024, due to the factors described above.

**Liquidity and Capital Resources**

We believe that our existing cash and cash equivalents, short and long-term investments, our cash flows from operations and our existing lines of credit provide us with the financial flexibility to meet our liquidity and capital needs. We expect to continue making investments in capital expenditures, assess acquisition opportunities, repurchase shares of our stock in accordance with our repurchase program, carry out research and development and invest in resources to strengthen our organization. The extent and timing of such expenditures may vary from period to period. Our future long-term capital requirements will depend on many factors including our level of sales, the impact of the economic environment on our growth, the timing and extent of spending to support development efforts, expansion of global sales and marketing activities, government regulation including trade sanctions and tariffs, the timing and introductions of new products, the need to ensure access to adequate manufacturing capacity and the continuing market acceptance of our products. In the near term, we will incur capital expenditures related to the expansion of capacity outside of Russia and Belarus. As of September 30, 2025, we had no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources.

------

<u>[Table](#i16ef846430f9402292f85303557ea7bd_7)[of Contents](#i16ef846430f9402292f85303557ea7bd_7)</u>

The following table presents our principal sources of liquidity:

---

| | | |
|:---|:---|:---|
| | **September 30,**<br>**2025** | **December 31,**<br>**2024** |
| | **(In thousands)** | **(In thousands)** |
| Cash and cash equivalents | $346026 | $620040 |
| Short-term investments | 524359 | 310152 |
| Unused credit lines and overdraft facilities | 222844 | 78115 |
| Working capital (defined as current assets excluding cash, cash equivalents and short-term investments, minus current liabilities) | 350747 | 295784 |

---

Included in cash and cash equivalents is $0.7 million of cash located in Belarus, as of September 30, 2025.

Short-term investments at September 30, 2025 consist of liquid investments including corporate bonds, commercial paper, U.S. Treasury and agency obligations and term deposits with original maturities of greater than three months but less than one year. See Note 4, "Fair Value Measurements" in the notes to the Condensed Consolidated Financial Statements for further information about our short-term investments.

The following table details our Credit Facilities as of September 30, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Description** | **Total Facility** | **Interest Rate** | **Maturity** | **Security** |
| U.S. Revolving Line of Credit <sup>(1)</sup> | $200.0 million | SOFR plus 1.25% to 1.45%, depending on our performance | June 2030 | Unsecured |
| Other Lines of Credit <sup>(2)</sup> | $22.0 million | Various | Various | Unsecured |
| Euro Credit Facilities (Germany) <sup>(3)</sup> | Euro 5.9 million ($6.9 million) | Various | Various | Unsecured, guaranteed by parent company |
| Euro Facility <sup>(4)</sup> | Euro 1.5 million<br>($1.8 million) | Euribor plus 1.25% | December 2025 | Common pool of assets of Italian subsidiary |

---

&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> At September 30, 2025, there were no drawings and no guarantees issued.

&nbsp;&nbsp;&nbsp;&nbsp;<sup>(2)</sup> Other lines of credit available to certain foreign subsidiaries in U.S. dollars and their respective local currencies. At September 30, 2025, there was $2.0 million drawn on these lines; and there were $2.2 million of guarantees issued against the lines which reduces total availability.

&nbsp;&nbsp;&nbsp;&nbsp;<sup>(3)</sup> The facilities are available to certain foreign subsidiaries in their respective local currencies. At September 30, 2025, there were no amounts drawn on this line; however, there were $3.7 million of guarantees issued against the lines which reduces total availability.

&nbsp;&nbsp;&nbsp;&nbsp;<sup>(4)</sup> At September 30, 2025, there were no drawings and no guarantees issued.

At September 30, 2025, our committed credit line is with Bank of America N.A. in the amount of $200.0 million. Under the credit agreement, we are required to meet certain financial covenants, which are tested quarterly and include an interest coverage ratio and a net leverage ratio. The interest coverage covenant requires we maintain a trailing twelve-month ratio of consolidated EBITDA to consolidated interest expense on all obligations that is at least 3.0 times. The net leverage covenant requires we maintain a trailing twelve-month ratio, which is the sum of all indebtedness for borrowed money on a consolidated basis, less cash and available marketable securities not classified as long-term investments in the U.S. in excess of $50 million up to a maximum of $500 million, to consolidated EBITDA that is less than 3.0 times. We were in compliance with the financial covenants as of September 30, 2025.

In addition to the financial covenants, the credit facility includes additional customary events of default, including non-payment of principal, interest or fees, violation of covenants, cross default to certain other indebtedness, invalidity of any loan document, material judgments, bankruptcy and insolvency events and change of control, subject, in certain instances, to cure periods. Upon the occurrence of an event of default, the lenders may elect to declare amounts outstanding under the Credit Agreement immediately due and payable.

The financial covenants in our loan documents may cause us to not make or to delay investments and actions that we might otherwise undertake because of limits on capital expenditures and amounts that we can borrow or lease. In the event that

------

<u>[Table](#i16ef846430f9402292f85303557ea7bd_7)[of Contents](#i16ef846430f9402292f85303557ea7bd_7)</u>

we do not comply with any one of these covenants, we would be in default under the loan agreement or loan agreements, which may result in acceleration of the debt, cross-defaults on other debt or a reduction in available liquidity, any of which could harm our results of operations and financial condition.

See Note 10, "Financing Arrangements" in the notes to the Condensed Consolidated Financial Statements for further information about our facilities.

The following table presents cash flow activities:

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** |
| | **(In thousands)** | **(In thousands)** |
| Cash provided by operating activities | $46535 | $174112 |
| Cash (used in) provided by investing activities | (292904) | 471279 |
| Cash used in financing activities | (50919) | (284609) |

---

*Operating activities.* Net cash provided by operating activities decreased by $127.6 million to $46.5 million for the nine months ended September 30, 2025 from $174.1 million for the nine months ended September 30, 2024, primarily due to an increase in cash used by working capital and a decrease in cash provided by net income after adding back non-cash expenses. Our largest working capital items typically are inventory and accounts receivable. Items such as accounts payable to third parties, prepaid expenses and other current assets and accrued expenses and other liabilities are not as significant as our working capital investment in accounts receivable and inventory because of the amount of value added within IPG due to our vertically integrated structure. Accruals and payables for personnel costs including bonuses and income and other taxes payable are largely dependent on the timing of payments for those items.

The decrease in cash flow from operating activities in first three quarters of 2025 when compared to the first three quarters of 2024 primarily resulted from:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• an increase in cash used by inventory as we manufactured more in the first three quarters of 2025 compared to the first three quarters of 2024 when we moderated our investments in inventory;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a decrease in cash provided by accounts receivable due to higher sales at the end of the first three quarters of 2025 and timing of collections;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• an increase in cash used by prepaid expenses and other assets due to timing of bank acceptance drafts and interest receivable; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• an increase in cash used by income and other taxes payable due to the timing of estimated tax payments made and refunds received from filing tax returns.

The decreases in cash provided by operating activities in the first three quarters of 2025 when compared to the first three quarters of 2024 were partially offset by:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a decrease in cash used by accrued expenses and other liabilities due to timing of payments for accrued personnel costs, cash provided by customer deposits, and timing of warranty activities, partially offset by lease payments and other activities; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• an increase in cash provided by accounts payable due to timing of payments.

*Investing activities.* Net cash used in investing activities was $292.9 million for the nine months ended September 30, 2025 as compared to cash provided by investing activities of $471.3 million in 2024. The cash used in investing activities in 2025 related to $232.7 million of net purchases of investments and $60.9 million of cash used for capital expenditures. The cash provided by investing activities in 2024 related to $543.0 million of net proceeds from short-term investments and $28.5 million of cash provided by sales of property, plant and equipment; partially offset by $75.4 million of cash used for capital expenditures, and $25.3 million of net cash outflow from the divestiture of our Russian operation. The cash proceeds from the sale of our Russian operation were lower than the cash and cash equivalents on hand, resulting in a cash outflow from divestiture.

*Financing activities.* Net cash used in financing activities was $50.9 million for the nine months ended September 30, 2025 as compared to net cash used of $284.6 million in 2024. The cash used in financing activities in 2025 primarily related to the purchase of treasury stock of $46.6 million and the net cash outflow from amounts disbursed in relation to shares withheld to cover employee income taxes due upon the vesting and release of restricted stock units of $4.3 million. The cash used in financing activities in 2024 primarily related to the purchase of treasury stock of $286.5 million.

------

<u>[Table](#i16ef846430f9402292f85303557ea7bd_7)[of Contents](#i16ef846430f9402292f85303557ea7bd_7)</u>

**Cautionary Statement Regarding Forward-Looking Statements**

This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and we intend that such forward-looking statements be subject to the safe harbors created thereby. For this purpose, any statements contained in this Quarterly Report on Form 10-Q except for historical information are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our businesses, or other characterizations of future events or circumstances are forward-looking statements.

The forward-looking statements included herein are based on current expectations of our management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to accurately predict and many of which are beyond our control. As such, our actual results may differ significantly from those expressed in any forward-looking statements. Factors that may cause or contribute to such differences include, but are not limited to, those discussed in more detail in Item 1, "Business" and Item 1A, "Risk Factors" of Part I of the Form 10-K filed with the SEC for the year ended December 31, 2024 (the "Annual Report") and in Item 1A, "Risk Factors" of Part II of the Form 10-Q filed with the SEC for the quarter ended March 31, 2025. Readers should carefully review these risks, as well as the additional risks described in other documents we file from time to time with the Securities and Exchange Commission. In light of the significant risks and uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to rely on such forward-looking information. We undertake no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

**Recent Accounting Pronouncements**

See Note 2 in the Notes to Condensed Consolidated Financial Statements for a full description of recent accounting pronouncements, including the respective dates of adoption or expected adoption and effects on our Condensed Consolidated Financial Statements contained in Item 1 of this Quarterly Report.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK** 

We are exposed to market risk in the ordinary course of business, which consists primarily of interest rate risk associated with our cash and cash equivalents and foreign exchange rate risk.

*Interest rate risk*. Certain of our financial instruments are subject to interest rate risk due to variable interest rates that fluctuate with market conditions. However, our exposure to market risk from interest rate fluctuations is limited. We maintain a portfolio of cash, cash equivalents, and short-term and long-term investments, which primarily includes bank deposits, money market funds, certificates of deposit, commercial paper, corporate bonds, and U.S. Treasury and agency securities. The majority of these investments mature within one year, although some corporate bonds have maturities approaching, but not exceeding, two years. Due to the short-term to intermediate-term nature of these instruments, we do not expect that a sudden change in market interest rates would have a material impact on our financial condition or results of operations.

We are also exposed to market risk as a result of increases or decreases in the amount of interest expense we must pay on our borrowings on our bank credit facilities. Although our U.S. revolving line of credit has variable rates, we do not believe that a 10% change in market interest rates would have a material impact on our financial position or results of operations.

*Exchange rates.* Due to our international operations, a significant portion of our net sales, cost of sales and operating expenses are denominated in currencies other than the U.S. dollar, principally the euro and the Chinese yuan. Changes in the exchange rate of the U.S. dollar versus the functional currencies of our subsidiaries affect the translated value and relative level of sales and net income that we report from one period to the next. In addition, our subsidiaries may have assets or liabilities denominated in a currency other than their functional currency which results in foreign exchange transaction gains and losses due to changes in the value of the functional currency versus the currency the assets and liabilities are denominated in. The loss on foreign exchange transactions totaled $1.5 million for the three months ended September 30, 2025 compared to a loss of $1.1 million for the three months ended September 30, 2024. Management attempts to minimize these exposures by partially or fully off-setting foreign currency denominated assets and liabilities at our subsidiaries that operate in different functional currencies. The effectiveness of this strategy can be limited by the volume of underlying transactions at various subsidiaries and by our ability to accelerate or delay inter-company cash settlements. As a result, we are unable to create a perfect offset of the foreign currency denominated assets and liabilities.

------

<u>[Table](#i16ef846430f9402292f85303557ea7bd_7)[of Contents](#i16ef846430f9402292f85303557ea7bd_7)</u>

At September 30, 2025, our material foreign currency exposure is net U.S. dollar denominated assets at subsidiaries where the euro is the functional currency and U.S. dollar denominated liabilities where the Chinese yuan is the functional currency. The net U.S. dollar denominated assets are comprised of cash, third party receivables and inter-company receivables offset by third party and inter-company payables denominated in U.S. dollar. The U.S. dollar denominated liabilities are comprised of inter-company payables. A 5% change in the relative exchange rate of the U.S. dollar to the euro as of September 30, 2025 applied to the net U.S. dollar asset balances, would result in a foreign exchange gain of $1.3 million if the U.S. dollar appreciated and a $1.4 million foreign exchange loss if the U.S. dollar depreciated. A 5% change in the relative exchange rate of the U.S. dollar to the Chinese yuan as of September 30, 2025 applied to the net U.S. dollar liabilities balances, would result in a foreign exchange loss of $1.3 million if the U.S. dollar appreciated and a $1.4 million foreign exchange gain if the U.S. dollar depreciated.

In addition, we are exposed to foreign currency translation risk for those subsidiaries whose functional currency is not the U.S. dollar as changes in the value of their functional currency relative to the U.S. dollar affect the translated amounts of our assets and liabilities. Changes in the translated value of assets and liabilities due to changes in functional currency exchange rates relative to the U.S. dollar result in foreign currency translation adjustments that are a component of other comprehensive income or loss on the Condensed Consolidated Statements of Comprehensive Income.

Foreign currency derivative instruments can also be used to hedge exposures and reduce the risks of certain foreign currency transactions; however, these instruments provide only limited protection and can carry significant cost. We have no foreign currency derivative instruments as of September 30, 2025. We will continue to analyze our exposure to currency exchange rate fluctuations and may engage in financial hedging techniques in the future to attempt to minimize the effect of these potential fluctuations. Exchange rate fluctuations may adversely affect our financial results in the future.

**ITEM 4. CONTROLS AND PROCEDURES**

**Evaluation of Disclosure Controls and Procedures**

Under the supervision of our chief executive officer and our chief financial officer, our management has evaluated the effectiveness of the design and operation of our "disclosure controls and procedures" (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of the end of the period covered by this Quarterly Report on Form 10-Q (the "Evaluation Date"). Based upon that evaluation, our chief executive officer and our chief financial officer have concluded that, as of the Evaluation Date, our disclosure controls and procedures are effective.

**Changes in Internal Controls**

There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act) that occurred during the quarter ended September 30, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

------

<u>[Table](#i16ef846430f9402292f85303557ea7bd_7)[of Contents](#i16ef846430f9402292f85303557ea7bd_7)</u>

**PART II—OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

Information with respect to this item may be found in Note 11, "Commitments and Contingencies" in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Quarterly Report and is incorporated herein by reference.

**ITEM 1A. RISK FACTORS**

In addition to the other information in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Item 1A of Part I of our Annual Report on Form 10-K for the year ended December 31, 2024, and in Item 1A, "Risk Factors" of Part II of the Form 10-Q filed with the SEC for the quarter ended March 31, 2025, which could materially and adversely affect our financial condition, results of operations or cash flows, or cause our actual results to differ materially from those projected in any forward-looking statements. We may also face other risks and uncertainties that are not presently known, are not currently believed to be material, or are not identified in our Annual Report or Quarterly Reports because they are common to all businesses.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

**Recent Sales of Unregistered Securities; Use of Proceeds from Registered Securities**

There have been no sales of unregistered securities for the three months ended September 30, 2025.

**Issuer Purchases of Equity Securities**

The following table reflects issuer purchases of equity securities for the three months ended September 30, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Total Number of Shares (or Units) Purchased (1)** | **Average Price Paid per Share (or Unit)** | **Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs (2)** | **Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs** |
| July 1, 2025 — July 31, 2025 | 110000 | $74.75 | 110000 | $11778 |
| August 1, 2025 — August 31, 2025 | 75614 | 76.53 | 74378 | 6084 |
| September 1, 2025 — September 30, 2025 | 30473 | 79.19 | 30030 | 3708 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total** | 216087 | $76.00 | 214408 | $3708 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) &nbsp;&nbsp;&nbsp;&nbsp;Total number of shares (or units) purchased includes shares repurchased as part of publicly announced plans or programs and "withhold to cover" tax liabilities upon vesting of restricted stock awards. For the three months ended September 30, 2025, a total of 1,679 shares were withheld to cover at an average price of $77.62.

&nbsp;&nbsp;&nbsp;&nbsp;(2) On February 13, 2024, we announced that our Board of Directors authorized the purchase of up to $300 million of IPG common stock (the "February 2024 authorization"), exclusive of any fees, commissions or other expenses. Share repurchases under these purchase authorization were made periodically in open-market transactions using our working capital, and were subject to market conditions, legal requirements and other factors. The share purchase program authorizations did not obligate us to repurchase any dollar amount or number of our shares, and repurchases could be commenced or suspended from time to time without prior notice.

We repurchased 214,408 shares in the third quarter of 2025 under the February 2024 authorization.

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

None.

**ITEM 4. MINE SAFETY DISCLOSURES**

Not applicable.

------

<u>[Table](#i16ef846430f9402292f85303557ea7bd_7)[of Contents](#i16ef846430f9402292f85303557ea7bd_7)</u>

**ITEM 5. OTHER INFORMATION**

During the Registrant's last fiscal quarter ended September 30, 2025, the following director of the Registrant adopted a Rule 10b5-1 trading arrangement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• on August 26, 2025, Ms. Agnes Tang, Director of the Registrant, adopted a Rule 10b5-1 trading arrangement for the sale of up to 3,392 shares over a period beginning November 24, 2025 and ending November 24, 2026 on the open market at prevailing prices, subject to minimum price thresholds.

Other than disclosed above, none of our directors or executive officers adopted, modified, or terminated a Rule 10b5-1 trading arrangement or "non-Rule 10b5-1 trading arrangement," in each case as defined in Item 408 of Regulation S-K during the quarter.

**ITEM 6. EXHIBITS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | Description |
| 10.1 | <u>[I](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex101-ipgamendedandrestate.htm)[PG Photonics Corporation Executive Severance Plan, amended and restated on September 30, 2025](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex101-ipgamendedandrestate.htm)[(incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed with the Commission on October 3, 2025)](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex101-ipgamendedandrestate.htm)</u> |
| 10.2 | <u>[Form of Severance Plan Participation Agreements dated Sep](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex102-formofseveranceplanp.htm)[tember 30, 2025 between the Registrant and each of Angelo](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex102-formofseveranceplanp.htm)[Lopresti, Timothy Mammen, Trevor Ness, and Dr. Igor Samartsev](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex102-formofseveranceplanp.htm)[(incorporated by reference to Exhibit 10.](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex102-formofseveranceplanp.htm)[2](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex102-formofseveranceplanp.htm)[to the Registrant's Current Report on Form 8-K filed with the Commission on October 3, 2025)](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex102-formofseveranceplanp.htm)</u> |
| 10.3 | <u>[IPG Photonics Corporation Senior Executive Annual Incentive Plan](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex103-ipgannualincentivepl.htm)[(incorporated by reference to Exhibit 10.](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex103-ipgannualincentivepl.htm)[3](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex103-ipgannualincentivepl.htm)[to the Registrant's Current Report on Form 8-K filed with the Commission on October 3, 2025)](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex103-ipgannualincentivepl.htm)</u> |
| 10.4 | <u>[Amendment to Employment Agreement between](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex104-amendmenttogitinempl.htm)[the Registrant and Dr. Mark Gitin, dated September 30, 2025](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex104-amendmenttogitinempl.htm)[(incorporated by reference to Exhibit 10.](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex104-amendmenttogitinempl.htm)[4](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex104-amendmenttogitinempl.htm)[to the Registrant's Current Report on Form 8-K filed with the Commission on October 3, 2025)](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex104-amendmenttogitinempl.htm)</u> |
| 10.5 | <u>[IPG Photonics Corporation](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex105-nonxemployeedirector.htm)[Non-Emplo](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex105-nonxemployeedirector.htm)[yee Director Compensation](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex105-nonxemployeedirector.htm)[Plan (incorporated by reference to Exhibit 10.](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex105-nonxemployeedirector.htm)[5](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex105-nonxemployeedirector.htm)[to the Registrant's Current Report on Form 8-K filed with the Commission on October 3, 2025)](https://www.sec.gov/Archives/edgar/data/1111928/000111192825000147/ex105-nonxemployeedirector.htm)</u> |
| 31.1 | <u>[Certification of Chief Executive Officer pursuant to Rule 13a-14(a)](ex311q32025.htm)</u> |
| 31.2 | <u>[Certification of Chief Financial Officer pursuant to Rule 13a-14(a)](ex312q32025.htm)</u> |
| 32 | <u>[Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 1350](ex32q32025.htm)</u> |
| 101.INS | Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |
| 101.SCH | XBRL Taxonomy Extension Schema |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |

---

------

<u>[Table](#i16ef846430f9402292f85303557ea7bd_7)[of Contents](#i16ef846430f9402292f85303557ea7bd_7)</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **IPG PHOTONICS CORPORATION** | **IPG PHOTONICS CORPORATION** |
| Date: November 4, 2025 | By: | /s/ Mark M. Gitin |
|  |  | Mark M. Gitin |
|  |  | Chief Executive Officer<br>(Principal Executive Officer) |
| Date: November 4, 2025 | By: | /s/ Timothy P.V. Mammen |
|  |  | Timothy P.V. Mammen |
|  |  | Senior Vice President and Chief Financial Officer <br>(Principal Financial Officer) |

---

## Exhibit 31.1

***Exhibit 31.1***

**Certification of Chief Executive Officer**

**Pursuant to Rule 13a – 14(a) or Rule 15d – 14(a) of the Securities Exchange Act of 1934**

I, Mark M. Gitin, certify that:

1. I have reviewed this quarterly report on Form 10-Q of IPG Photonics Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be signed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 4, 2025

---

| | |
|:---|:---|
| By: | /s/ Mark M. Gitin |
|  | **Mark M. Gitin** |
|  | **Chief Executive Officer (Principal Executive Officer)** |

---

## Exhibit 31.2

***Exhibit 31.2***

**Certification of Chief Financial Officer**

**Pursuant to Rule 13a – 14(a) or Rule 15d – 14(a) of the Securities Exchange Act of 1934**

I, Timothy P.V. Mammen, certify that:

1. I have reviewed this quarterly report on Form 10-Q of IPG Photonics Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 4, 2025

---

| | |
|:---|:---|
| By: | /s/ Timothy P.V. Mammen |
|  | **Timothy P.V. Mammen** |
|  | **Senior Vice President and Chief Financial Officer (Principal Financial Officer)** |

---

## Ex-32

***Exhibit 32***

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the filing of the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025 (the "Report") by IPG Photonics Corporation (the "Company"), Mark M. Gitin, as the Chief Executive Officer of the Company, and Timothy P.V. Mammen, as the Chief Financial Officer of the Company, each hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

---

| | |
|:---|:---|
| 1 | the Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and |
| 2 | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |

---

Date: November 4, 2025

---

| |
|:---|
| /s/ Mark M. Gitin |
| **Mark M. Gitin** |
| **Chief Executive Officer** |
| /s/ Timothy P.V. Mammen |
| **Timothy P.V. Mammen** |
| **Senior Vice President and Chief Financial Officer** |

---

A signed original of this written statement required by 18 U.S.C. Section 1350 has been provided to IPG Photonics Corporation and will be retained by IPG Photonics Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

<br>